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ABSTRACT 
Streptococcus pneumoniae (pneumococcus) is commonly found in the 
nasopharynx of healthy individuals, yet it can be a serious pathogen, particularly in the 
lower respiratory tract, where it can cause severe pneumonia.  During pneumococcal 
pneumonia, anti-bacterial host defense requires the orchestrated expression of innate 
immunity mediators, initiated by alveolar macrophages and dependent on transcriptional 
activity driven by Nuclear Factor-κB (NF-κB).  Although the initiation of a pulmonary 
inflammatory response is critical to anti-pneumococcal defense during pneumonia, how 
differences in pneumococcal-macrophage interactions can influence this process is 
unclear. To determine the functional significance of varying macrophage NF-κB 
activation, we examined macrophage responses to pneumococcal stimulation in culture 
and in mice. Macrophage-pneumococcal interactions resulted in the induction of varied 
NF-κB activation.  Two main pathways were revealed regarding host response and 
disease outcome. Pneumococci that induced efficient macrophage NF-κB activation 
resulted in robust anti-pneumococcal lung defense and bacterial clearance.  Conversely, 
failure to activate effective macrophage NF-κB signaling resulted in an altered 
macrophage response of necroptosis. Overall, we conclude that varying levels of 
		 viii 
macrophage NF-κB activation by pneumococcus can directly influence the severity of 
infection.  Furthermore, inefficient macrophage NF-κB activation can also have cytotoxic 
effects on these critical lung resident cells during pneumonia.  
The induction of macrophage NF-κB activation by S. pneumoniae is as diverse as 
the population of pneumococcal isolates in the community.  A unique host-pathogen 
interaction exists between pneumococcus and the alveolar macrophage that plays an 
important role in anti-pneumococcal defense during pneumonia and in the prevention of 
cytotoxic consequences induced by virulent pneumococci.  This interaction suggests that 
therapies, which modulate NF-κB activation, hold promise for augmenting resistance and 
ameliorating deleterious effects during pneumococcal pneumonia that could lead to the 
development of severe disease.  
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PREFACE 
Five years ago, I started what I thought was the perfect project that allowed me to 
extend my interest in microbial pathogenesis to the study of acute respiratory infections. 
When I was first introduced to the underlying premise of my project, I immediately saw 
the potential to investigate a very interesting question—“How can we better understand 
the dynamic and diverse range of disease outcome seen in individuals with pneumococcal 
lung infections?” I was intrigued by the potential of this project to allow me to investigate 
both sides of the story (taking into account both host and pathogen). What seemed like a 
straightforward plan of investigation, turned out to be a long process of generating new 
tools, animal models, and imaging techniques to obtain answers to really important 
questions about pneumococcal pneumonia. This thesis is a report of this long and arduous 
process.  However, it cannot fully express the long days spent in the lab trouble-shooting, 
battling self-doubt, and digging deeply to present the completed work displayed here 
motivated by the simple love of scientific inquiry.   
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CHAPTER I: INTRODUCTION 
THE PNEUMOCOCCUS 
A	Brief	History		
	
 Streptococcus pneumoniae is a classic example of a highly invasive bacterial 
pathogen (Henriques-Normark and Tuomanen, 2013) and known as one of the leading 
causes of bacterial disease among the very young and very old (Weiser et al., 1994).  S. 
pneumoniae was first isolated simultaneously by George Miller Sternberg in the United 
States and Louis Pasteur in France in 1881 (Watson, 1993, Austrian, 1999). Based on its 
tendency to cause pulmonary disease, it was later referred to as Pneumococcus.  By 1920, 
Pneumococcus was renamed Diplococcus pneumoniae, referring to pairs of cocci causing 
pneumonia (Tomasz et al., 1964).  It was not until 1974 that the pneumococcus was 
actually given its present name of Streptococcus pneumoniae based on its characteristic 
growth as chains of cocci in liquid media (Watson, 1993)  
 Lacking an environmental reservoir, pneumococcus is commonly carried 
asymptomatically in the nasopharynx of healthy individuals (Weiser, 2010). Despite its 
commensal nature, interactions with humans are complex and range in disease outcomes.  
Colonization, due to spread from person to person by droplets/aerosol, is a prerequisite 
for pneumococcal disease (van der Poll and Opal, 2009, Bogaert et al., 2004). Adherence 
to the epithelial lining of the respiratory tract is required for S. pneumoniae colonization 
and involves pneumococcal binding to cell-surface carbohydrates (such as N-acetyl-
glycosamine) found on the non-inflamed epithelium (Bogaert et al., 2004, Henriques-
Normark and Tuomanen, 2013).  Within in the nasal cavity, the negatively charged 
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pneumococcal capsule protects pneumococcus from being trapped in mucous and allows 
for successful attachment to the nasopharyngeal epithelium to establish colonization 
(Henriques-Normark and Tuomanen, 2013).  Colonization can persists for weeks in 
adults or months in children without any serious consequence of disease (Kadioglu et al., 
2008, Bogaert et al., 2004). However, conversion of asymptomatic colonization to 
invasive disease can occur (Table 1) (Bogaert et al., 2004).  Inflammatory factors (such 
as interleukin-1 and tumor necrosis factor) that change the type and number of receptors 
on target epithelial and endothelial cells (Bogaert et al., 2004, Henriques-Normark and 
Tuomanen, 2013, Weiser, 2010) can lead to nasopharyngeal carriage progressing into the 
middle-ear space causing otitis media, the terminal airways of the lungs causing 
community-acquired pneumonia, and the meninges of the brain causing bacterial 
meningitis (Henriques-Normark and Tuomanen, 2013, Weiser, 2010, Bogaert et al., 
2004). As a frequent colonizer of the upper respiratory tract, the potential for S. 
pneumoniae to readily convert from asymptomatic colonization to a wide range of 
invasive diseases (Weiser, 2010) qualifies it as one of the most important causes of 
invasive disease in human populations throughout the world (Kadioglu et al., 2008, van 
der Poll and Opal, 2009, Ortqvist et al., 2005). 
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Table 1. Pathogenic Routes of Infection for S. Pneumoniae and Clinical Outcomes  
INFECTED ORGANS CLINICAL OUTCOME 
Sinuses Sinusitis 
Middle ear Otitis media 
Alveoli Pneumonia 
Pleura Empyema 
Pericardium Empyema 
Blood Septicemia 
Peritoneum Peritonitis 
Joints Arthritis/Osteomyelitis 
Meninges Meningitis 
Information in this table was adapted from: (Bogaert et al., 2004)	
 
Microbial Features 
S. pneumoniae are Gram-positive, catalase-negative, facultative anaerobic 
bacteria of the phylum Firmicutes.  Under the microscope, they are visualized as lancet-
shaped cocci (elongated spheres with a slightly pointed outer curvature) measuring less 
than 2 micrometers (between 0.5–1.25µm) in diameter forming pairs of cocci 
(diplococcic) or single spheres combined in short chains. Pneumococcal cells are non-
motile and do not form spores (Firshein, 2013).  
 Pneumococci are covered in a polysaccharide capsule that overlays the cell wall 
containing peptidoglycan and a unique teichoic acid chemical structure (a ribitol 
phosphate backbone and covalently attached phosphorylcholine) (van der Poll and Opal, 
2009). The capsular polysaccharide is antigenic and forms the basis for classifying 
pneumococci by serotypes.  By 1940, more than 80 serotypes had been described 
(Watson, 1993).  Currently, there are over 90 recognized serotypes of S. pneumoniae, 
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each of which produce a structurally distinct capsular polysaccharide (Morona et al., 
1999).  
 
Clinical Significance 
As discussed previously, the ecological niche for pneumococcus is the 
nasopharynx of young children. However, if pneumococcus gains access to the normally 
sterile sites of the airways, serious disease can develop (Kadioglu et al., 2008, Henriques-
Normark and Tuomanen, 2013).  According to the Centers for Disease Control (CDC), 
pneumococcus is a common cause of acute otitis media and detected in 28%–55% of 
middle ear aspirates.  By age 12 months, more than 60% of children have had at least one 
episode of acute otitis media.  Pneumococcal infections are also cause for over 50% of all 
cases of bacterial meningitis in the United States—reports showing an estimated 3,000 to 
6000 cases of pneumococcal meningitis occurring each year. Furthermore, among 
children ages 2-years and younger, bacteremia without a known site of infection is the 
most common invasive clinical presentation of pneumococcal infection (accounting for 
~70% of invasive disease) (Austrian, 1999). In Europe and North America alone, 
community-acquired pneumonia is known as one of the most common, serious infections 
in children, with an annual incidence of 34 to 40 cases per 1,000 children (Ostapchuk et 
al., 2004, Juven et al., 2000) and pneumococcus being the most common causative agent 
(van der Poll and Opal, 2009, Cevey-Macherel et al., 2009).  
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PNEUMONIA 
A Brief Description of the Healthy Lung 
The lungs are a pair of cone-shaped, spongy, air-filled organs that take up the 
majority of the chest cavity. One lung is positioned on the right side of the chest and the 
other is on the left. Each lung is made up of sections called lobes and they work together 
to bring in vital oxygen into the body and remove the unwanted waste product, carbon 
dioxide (Agur and Dalley, 2012).  Within the lungs exists an elaborate branching of 
tubules (bronchi) that subdivide into smaller airways (bronchioles) and terminate into 
millions of highly vascularized microscopic air-filled sacs (alveoli) where the exchange 
of oxygen and carbon dioxide occurs (Guyton and Hall, 2000, Kopf et al., 2015).  
The process of ventilation (movement of air between the environment and the 
lungs) moves millions of liters of air through the highly branched conducting airways to 
the alveoli (Whitsett and Alenghat, 2015).  However, in addition to air, it has been 
estimated that a typical human adult inhales an impressive load of contaminants into the 
lungs on a daily basis (airborne impurities present in approximately 11,000 liters of air) 
(Mizgerd, 2012, Prince, 2013, Martin and Frevert, 2005).  In other words, the lungs are 
not simply an open door to the environment but to disease causing agents and microbes 
(Chiu and Openshaw, 2015, Prince, 2013) such as bacteria, viruses, fungi and protozoans. 
Although, the healthy respiratory tract is equipped with innate immune defenses that 
provide physical and immunological barriers against inspired microbes. Most air 
contaminants, such as bacteria or viruses, are filtered out and kept from entering the 
lower airways and infecting the lungs (Moldoveanu et al., 2009).  However, it should be 
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noted that the continual exposure of the respiratory tract to the air does allow for frequent 
colonization of the upper airways by organisms such as S. pneumoniae, which can initiate 
severe infection if they gain access to the lower airways.  Successful entry into the lower 
airways often begins with colonization and aspiration of upper airway flora is a common 
cause of acute lower respiratory tract infections (Brown et al., 2015, Prince, 2013).   
 
Pneumococcal Pneumonia: Pneumococcus in the Airways 
Pneumonia is a severe acute lower respiratory tract infection in which the alveoli 
(responsible for absorbing oxygen from the atmosphere) are flooded with fluid and 
immune cells (Guyton and Hall, 2000, Burns et al., 2003). Pneumonia’s impact as an 
infectious disease has had a long-standing reputation. Nearly a century ago, Dr. William 
Osler, the founder of modern medicine, described pneumonia as the “captain of all the 
men of death” (van der Poll and Opal, 2009). Since the early 1990s, when the disability-
adjusted life years lost metric began to be used, the greatest disease burden worldwide 
has consistently been reported as acute lower respiratory infection (Mizgerd, 2012). 
Pneumonia is among the most common causes of death in children worldwide and the 
most common reason for children to be hospitalized in the United States (Scott et al., 
2012, Mizgerd, 2012, Vos et al., 2012, Yu et al., 2011, Armstrong et al., 1999, Black et 
al., 2010). For the elderly, similar statistics show that approximately half of all infectious 
disease hospitalizations and deaths in the US are from pneumonia (Quinton and Mizgerd, 
2015).  
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Throughout the 20th century, mortality rates due to pneumonia have oscillated.  
For example, during the early part of the century, U.S. pneumonia mortality rates 
drastically declined due to the introduction of healthier/sanitary lifestyle practices.  
However, the influenza epidemic of 1918 broke this trend of decreased mortality by 
quadrupling the mortality rates (Mizgerd, 2012). With the advent of antibiotic use in the 
mid 20th century, a more substantial decline in deaths due to pneumonia was observed.  
Interestingly, the rate of deaths due to pneumonia have not change drastically since that 
time (Armstrong et al., 1999).   
Although pneumonia is a lung disease caused by a variety of pathogens, such as 
bacterial Streptococcus, Staphylococcus, Pseudomonas, Haemophilus, Chlamydia and 
Mycoplasma, several viruses, and certain fungi and protozoans (Musher and Thorner, 
2014), the relationship between pneumonia and S. pneumoniae has been profound.  In the 
early 1880s, the causative role of S. pneumoniae in pneumonia was firmly established 
and further described by Friedlander and Talamon in 1883 (Watson, 1993). In the pre-
antibiotic era, pneumococcus was known to cause 95% of cases of pneumonia (Musher 
and Thorner, 2014) making it a formidable pathogen of lung disease.  In the current era of 
antibiotics and multiple pneumococcal vaccines, pneumonia often results from viruses or 
pathogens that could not be found, but pneumococcus remains the most commonly 
identified bacterial cause of pneumonia (Jain et al., 2015).  Still today, pneumococcus 
remains a common and important cause of pneumonia (Musher and Thorner, 2014, 
Mizgerd, 2012).   
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INNATE IMMUNE DEFENSE AGAINST PNEUMONIA 
Inflammation: Host Response During Pneumococcal Pneumonia 
  Pulmonary immunity functions to protect the lung from infection and preserve 
normal respiratory activities (Mizgerd, 2008, Moldoveanu et al., 2009, Martin and 
Frevert, 2005). When microbes such as bacteria enter the lungs, the microbial interactions 
with the respiratory tract initiate an immune response critical to resistance (Quinton and 
Mizgerd, 2015, Moldoveanu et al., 2009, Prince, 2013). The lung is well equipped to 
fight infection.  Upon minor microbial intrusion into the airways (such as a small number 
of microbes and/or less virulent microbes) resident defenses such as the mucociliary 
escalator or resident macrophages are able to readily clear the infection. However, in the 
event more virulent or numerous microbes enter the lungs (initiating an acute infection), 
inflammation is required for anti-microbial defense (Mizgerd, 2012, Quinton and 
Mizgerd, 2011, Moldoveanu et al., 2009, Prince, 2013).   
The inflammatory response is characterized by the coordinated activation of 
various signaling pathways that regulate expression of both pro- and anti-inflammatory 
mediators by resident tissue cells, such as alveolar epithelial cells and alveolar 
macrophages, and by neutrophils and other leukocytes recruited from the blood (Quinton 
and Mizgerd, 2015, Martin and Frevert, 2005, Moldoveanu et al., 2009). During 
pneumococcal pneumonia, an acute inflammatory response is initiated involving cytokine 
production, leukocyte recruitment, and plasma extravasation facilitated by chemokines 
and upstream signaling from early response cytokines, such as TNF-α and IL-1 
(Mizgerd, 2008, Eisele and Anderson, 2011, Prince, 2013). The clinical manifestation of 
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the inflammatory response in the lungs include: 1) the alveoli filling with serous edema, 
which facilitates the growth and spread of pneumococci to adjacent alveoli and interferes 
with gas exchange. 2) Alveoli being infiltrated by red blood cells and unsuccessful 
professional phagocytes (early consolidation); and neutrophils being recruited to the 
lungs. 3) Neutrophils predominating in the consolidated alveoli (late consolidation) and 
lungs becoming damaged—impairing gas exchange. 4) Scavenging macrophages 
replacing neutrophils and clearing debris from the inflammatory response; and restoring 
lung architecture to normal (West and West, 2013).  This inflammatory process is critical 
for the clearance of invading pneumococci (Pittet et al., 2011, Jones et al., 2005, 
Aberdein et al., 2013) because it functions to bring in neutrophils into the infected 
airspaces in a timely and efficient manner (Mizgerd, 2008, Eisele and Anderson, 2011, 
Moldoveanu et al., 2009).   
 
NF-κB: Mediator of Innate Immune Responses 
Upon encounter with microbes, the respiratory tract involves innate immunity to 
establish and maintain resistance to infection.  The innate immune responses to lung 
pathogens involve the coordinated expression of many affector and effector molecules of 
innate immunity, which must be initially induced and subsequently tightly regulated in 
response to microbial interaction (Quinton and Mizgerd, 2011). A critical mediator of 
innate immune responses is the activation of the canonical NF-κB signaling pathway 
(Quinton and Mizgerd, 2015, Hatada et al., 2000, Christofferson et al., 2014, Baeuerle 
and Henkel, 1995, Kopp and Ghosh, 1995).  
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NF-κB is a family of transcription factors, which is expressed in all nucleated 
cells.  In resting cells, NF-κB is mostly found constrained to the cytoplasm due to 
inhibitor kappa B (IκB) proteins.  Upon activation (such as by microbial stimulation), a 
signaling cascade involving multiple adaptors (e.g. TNFR-associated factor, myeloid 
differentiation primary response protein 88, and TIR domain containing adaptor protein) 
as well as intermediate transducing molecules and kinases (e.g. IL-1R associated kinases 
and receptor-interacting proteins) lead to the phosphorylation (by the cytokine-responsive 
IκB kinases IKKα and β) and degradation (by the 26S proteasome) of the inhibitory IκB 
proteins that liberates the NF-κB dimers and allows for nuclear translocation where it can 
regulate gene transcription (Kopp and Ghosh, 1995, Hatada et al., 2000, Rahman and 
McFadden, 2011).  NF-κB is made up of five different proteins (p50, p52, RelA (p65), c-
Rel, and RelB) but only two subunits (p65 and p50) have been identified as being 
involved in pulmonary responses to microbial stimulation (Mizgerd, 2002, Hatada et al., 
2000, Kopp and Ghosh, 1995).    
  The role of NF-κB during infection is best understood as a molecular fulcrum, 
which balances the initial innate immune response to microbes in the lungs (Rahman and 
McFadden, 2011, Quinton and Mizgerd, 2015).  As previously discussed, the lungs are 
well equipped with resident cells that play an important role in antimicrobial defense.  In 
the particular case of pneumococcal lung infection, specific cells are critical to bacterial 
resistance.  For example, when pneumococcus enters the lung, the alveolar macrophages 
are instrumental in coordinating the earliest events of host defense mediated by NF-κB 
activation (Mizgerd, 2012, Pittet et al., 2011, Prince, 2013, Moldoveanu et al., 2009). 
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Alveolar Macrophage: Sentinels of the Lung  
The lungs contain at least three different types of macrophages (bronchial, 
interstitial, and alveolar).  In the uninfected lung, alveolar macrophages (the specialized 
tissue macrophages that reside in the alveolar space) make up approximately 90–95% of 
the cell content that can be recovered by lavage, and are well in position to function as a 
first line of defense in the lower airways (Kopf et al., 2015, Martin and Frevert, 2005, 
Prince, 2013).  
The alveolar macrophage is a specialized lung cell that stands guard at the 
alveolar-blood interface within the alveolus and patrols and clears the alveolar surfaces of 
inhaled toxic, allergic, or infectious particles (Rubins, 2003, Martin and Frevert, 2005). In 
addition, alveolar macrophages also function as regulators of innate alveolar defenses 
against serious respiratory infection. For example, when larger numbers of infectious 
particles or virulent microbes move into the alveolar space, alveolar macrophages 
effectively make and secrete cytokines and chemokines to initiate inflammatory 
responses and recruit activated neutrophils into the infected air spaces. These alveolar 
macrophage cytokines subsequently serve as an alarm system that alerts epithelial cells, 
endothelial cells, neutrophils, hepatocytes, and other cells to the presence of pathogens in 
the lung. In the particular case of pneumococcal infection, alveolar macrophages are 
largely responsible for the initial recognition and elaboration of cytokine signals that 
coordinate the earliest steps of host defense (Mizgerd, 2012, Pittet et al., 2011, 
Moldoveanu et al., 2009) 
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HOST-MICROBE INTERACTIONS DURING  
PNEUMOCOCCAL PNEUMONIA  
Lung Cells Involved in Host Defense  
During pneumococcal pneumonia, host defense relies heavily on innate immune 
mechanisms to prevent invasion of pathogens (Eisele and Anderson, 2011).  Many cells 
are involved in pulmonary clearance, such as alveolar epithelial cells, alveolar 
macrophages, and neutrophils.  Each of these distinct cell populations play important 
roles in eradicating pneumococcus from the lower airways and possess unique host 
resistance mechanisms against pneumococcal lung infection.    
Epithelial cells, the surface cells of the respiratory tract, respond to respiratory 
infection by producing a number of bactericidal compounds such as IgA, collectins, and 
defensins (Eisele and Anderson, 2011).  There are two types of alveolar epithelial cells: 
Type 1 and Type II (also called pneumocytes).  Type I cells function mainly in gas 
exchange but they can also sense and respond to microbial products.  The Type II cells 
function as critical airway defenders that secrete antimicrobial products, sense pathogenic 
invasion, and produce cytokines and chemokines essential for the activation and 
deactivation of inflammation (Moldoveanu et al., 2009, Eisele and Anderson, 2011).  
These cells are well poised for microbial combat as they have direct, initial contact with 
the environment and widely express Toll-like receptors (TLRs) and NOD-like receptors 
(NLRs) that allow for quick responses to specific gene products known as pathogen-
associated molecular patterns (PAMPs) and activate innate immune signaling (Whitsett 
and Alenghat, 2015, Eisele and Anderson, 2011).  
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Upon entering the lungs, pneumococci encounter alveolar macrophages, the 
resident phagocytes that patrol and clear the airspaces of particulate matter, toxicants, and 
microbes (Aberdein et al., 2013). These hearty cells are long-lived and able to withstand 
the harsh environment of acute inflammation and remain present following resolution 
(Kopf et al., 2015).  The alveolar macrophage can recognize S. pneumoniae by a variety 
of surface receptors such as: FC receptors that recognize the Fc component of cognant 
immunoglobulin bound bacteria; complement receptors CR1, CR3, and CR4 which 
recognize C3b stabilized on the bacterial surface; macrophage scavenger receptors; 
platelet-activating factor receptors; and Toll family receptors (Gordon et al., 2000). Early 
detection of pneumococci by alveolar macrophages results in many host defense 
mechanisms critical to eradicating live pneumococcus from the lungs, such as 
phagocytosis, apoptosis of alveolar macrophages, and activation of alveolar macrophages 
that will subsequently lead to an acute inflammatory response (Prince, 2013).   
The hallmark of early cellular influx to the lung airspace during pneumococcal 
infection is the presence of neutrophils (Prince, 2013).  Neutrophils are known as 
professional antimicrobial effector cells as they take up and kill invading bacteria using 
both oxidative and non-oxidative mechanisms (Standish and Weiser, 2009).  Recruited by 
the cell signaling efforts of alveolar macrophages and epithelial cells (Jones et al., 2005, 
Quinton et al., 2007), neutrophil host defense mechanisms include: phagocytosis, 
degranulation, respiratory burst, and release of neutrophil extracellular traps (NETs) 
(Kolaczkowska and Kubes, 2013). In addition to their effector cell functions, neutrophils 
are also important sources of immune mediators like cytokines and eicosanoids that can 
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influence the innate and adaptive immune responses during pneumonia (Quinton and 
Mizgerd, 2015). During pneumococcal infection, neutrophils are among the first cells to 
be recruited to the lungs to execute opsonin-dependent phagocytosis of the 
pneumococcus. Neutrophils are critical to anti-pneumococcal defense and absence of 
these cells can be detrimental during pneumonia (Standish and Weiser, 2009).  
  
Microbial Factors that Influence Infection  
Upon bacterial infection, the goal of bacteria is to multiply (Peterson, 1996). 
Microbial properties produced by a microorganism to help it establish infection, avoid 
death, and cause disease are called virulence factors. The efficacy of a given virulence 
factor is related to the ability of a pathogen to establish infection despite host resistance 
mechanisms (Casadevall and Pirofski, 2001).  Bacteria possess a number of virulence 
factors that help to increase infectivity and promote growth within the host.  S. 
pneumoniae has a number of virulence factors (Table 2) that are too numerous to be 
discussed here, in detail (Kadioglu et al., 2008, van der Poll and Opal, 2009).  However, 
several of these virulence factors may be directly related to macrophage-pneumococcal 
interactions and have been chosen to be the main focus of this section.  Specific examples 
of these pneumococcal virulence factors include: endotoxin, cell-surface proteins, and 
capsule (Peterson, 1996).  
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Table 2.  Streptococcus pneumoniae Virulence Factors 
VIRULENCE FACTOR MECHANISM OF VIRULENCE 
Capsule -Inhibits effective opsonophagocytosis 
-Low immunogenicity of some serotypes 
-Prevents entrapment in the nasal mucus, which 
allows for access to epithelial surface 
Cell wall -Activates the alternative complement pathway 
and anaphylatoxin production 
-Enhances vascular permeability 
-Mediates attachment to endothelial cells 
Phosphocholine -Bacterial adhesion that enhances persistence in 
the upper respiratory tract 
Choline-binding protein A -Binds to human secretory component on a 
polymeric Ig receptor during the first stage of 
translocation across the epithelium 
Bacteriocin (pneumocin) -Bacterial peptides that target other bacteria 
Pneumococcal Surface Protein A (PspA) -Prevents complement activation by blocking 
binding of C3 onto pneumococcal surface 
Pneumococcal Surface Protein C (PspC) -Complement Factor H-binding component 
Pneumolysin (Ply) -Cytolytic toxin that creates pores in 
cholesterol-containing membranes and causes 
host cell lysis 
Autolysin A (LytA) -Digests the cell wall and releases pneumolysin 
Peptide permeases -Enhance adhesion 
Neuraminidase (NanA);  
β-N-acetylglucosaminidase (BgaA);  
β-galactosidase (StrH) 
-Act sequentially to cleave terminal sugars 
form human glycoconjugates, which might 
reveal receptors for adherence 
IgA1 protease -Cleaves human IgA1; limits the effectiveness 
of the host humoral response 
Hyaluronate lyase (Hyl) -Breaks down hyaluronan-containing 
extracellular matrix components 
Pneumococcal adhesion and virulence A 
(PavA) 
-Binds to fibronectin 
Enolase (Eno) -Binds to plasminogen 
Pneumococcal surface antigen A -Component of the ATP-binding cassette 
(ABC) transport system involved in resistance 
to oxidative stress 
Pneumococcal iron acquisition A (PiaA); 
Pneumococcal iron uptake A (PiuA) 
-Component of the ABC transport system 
Hydrogen Peroxide (H2O2) -Produced by pneumococci and contribute to 
lung tissue damage  
This table displays a number of key pneumococcal virulence factors but it is not an 
exhaustive list.  Information in this table was adapted from: (Kadioglu et al., 2008, 
AlonsoDeVelasco et al., 1995).	
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Exotoxins are toxic proteins released from bacterial cells.  They can be grouped 
into several categories, such as cytoxins, neurotoxins, and enterotoxins based on their 
biologic effect on different host cells (Peterson, 1996). Pneumolysin is a 53-kDa thiol-
activated cholesterol-dependent, pore-forming exotoxin produced by pneumococcal 
isolates (Tuomanen, 2004). In addition to its cytotoxic, pore-forming capability, 
pneumolysin has also been shown to be able to activate the classical complement 
pathway by binding to the Fc region of human IgG (Tuomanen, 2004), neutrophils, and 
macrophages at sites of infection (Dockrell et al., 2012).  Pneumolysin is a well-known 
virulence factor for pneumococci that can cause significant damage to airway cells during 
lung infection and drastically alters their function (Prince, 2013, Kadioglu et al., 2008, 
Hirst et al., 2004, Dockrell et al., 2012). Pneumococcal pathogenesis has been linked to 
pneumolysin’s ability to interfere with phagocytic and ciliary clearance of pneumococci 
by blocking humoral immune responses and allowing for host tissue invasion 
(Tuomanen, 2004).  The damaging effects on cells have been shown to be due to its 
ability to inhibit the bactericidal activity of leukocytes, block the proliferative responses 
of T cells and Ig production of B cells, reduce ciliary beating of human respiratory 
epithelium and the direct cytotoxicity for respiratory endothelial and epithelial cells 
(Tuomanen, 2004, Dockrell et al., 2012, Marriott et al., 2008).   
Surface proteins facilitate bacterial translocation across anatomical barriers within 
the host, such as in the case of moving from tissues into the blood.  For example, 
Pneumococcus expresses a number of surface proteins belonging to the choline binding 
protein (Cbp) family.  These surface proteins are unique to pneumococcus.  Cell-wall 
		
17 
associate surface proteins (such as pneumococcal surface adhesion A—PsaA) mediates 
pneumococcal binding to N-acetyl-glycosamine on the epithelium during colonization 
(Bogaert et al., 2004). Pneumococcal surface binding protein A (PspA) is a specific 
choline binding protein that interferes with the uptake of pneumococci into phagocytes by 
inhibiting complement deposition and activation. (Henriques-Normark and Tuomanen, 
2013).  PspA is highly electronegative, which is believed to prevent complement binding 
to bacterial cell surface (Kadioglu et al., 2008). Choline-binding protein A (CbpA) has 
been shown to directly interact with polymeric Ig receptors, which facilitates 
pneumococcal migration through the mucosal barrier.  In addition, CbpA is able to bind 
to the secretory component of IgA and directly interfere with host immune responses 
(Bogaert et al., 2004). 
Capsule formation by many bacteria is a well recognized protective mechanism 
for bacteria to enhance their survival within the host (Peterson, 1996).  On the surface of 
S. pneumoniae is a highly heterogeneous polysaccharide capsule that forms its outermost 
layer.  The pneumococcal capsule ranges from approximately 200–400 nm in thickness, 
with the exception of specific serotypes (such as serotype 3) that are known to have 
uncharacteristically large capsules (Kadioglu et al., 2008).   During colonization, it has 
been shown that the presence of the polysaccharide capsule functions to reduce 
entrapment by mucus within the nasal cavity, thereby allowing for epithelial surface 
attachment (Kadioglu et al., 2008). In addition, the polysaccharide capsules are anti-
phagocytic and present steric hindrance to leukocytes involved in complement fixation 
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(Henriques-Normark and Tuomanen, 2013, Bogaert et al., 2004), which further 
contributes to some of S. pneumoniae’s immune evasion strategies during infection.    
 
Virulence: An Outcome of Host-Microbe Interactions 
Traditionally, the word virulence has been used to describe microbial 
characteristics, such as its relative capacity to cause disease (Peterson, 1996).  However, 
information about disease progression gleaned from infectious disease studies, including 
lower respiratory tract infections, challenge this antiquated and perhaps incomplete 
definition of virulence. For example, as bacteria enter the lower respiratory tract, 
pneumonia is initiated, yet it is the physiological processes which incorporate responses 
from diverse cell types that dictate the outcome of the respiratory infection (Quinton and 
Mizgerd, 2015). In other words, the severity of the lung infection is predicated on the 
balance between the bacterium’s ability to cause disease and the level of host resistance 
(Peterson, 1996).  Therefore, it is conceivable to think of virulence as a possible outcome 
of host‐microbe interactions (Casadevall and Pirofski, 2001) and apply this perspective to 
a study of pneumococcal pneumonia that investigates both microbial and host variables 
during infection.  
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SPECIFIC AIMS AND HYPOTHESIS 
As described earlier, pneumococcus causes an array of clinical outcomes, such as 
acute otitis media, sinusitis, meningitis, and pneumonia—the latter being the greatest 
cause of infection-related deaths in the United States. Much of what is known about 
pneumococcal disease progression emphasizes the polysaccharide capsule as a prominent 
virulence factor. However, it has been observed that even within a given serotype, 
different isolates have varying abilities to cause disease, which would suggest that these 
differences were due to virulence factors independent of the capsule. Therefore, 
elucidation of other virulence properties would greatly enhance our understanding of the 
range of disease pathogenesis seen in patients. Macrophage NF-κB activation and 
cytokine expression direct innate immunity in the lungs during pneumococcal infection. 
We propose that pneumococcal avoidance of this response is an unrecognized and critical 
virulence determinant. For this proposal we use a novel in vitro macrophage bioassay to 
investigate the differences among pneumococcal isolates and their ability to activate 
macrophage NF-κB, as well as a unique source of patient-derived clinical isolates of S. 
pneumoniae. We hypothesize that different community isolates of S. pneumoniae vary in 
their ability to activate macrophage NF-κB and those that avoid macrophage activation 
are more likely to cause pneumonia.   
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CHAPTER II: MATERIALS AND METHODS 
 
BACTERIA 
Laboratory Isolates of S. pneumoniae 
S. pneumoniae laboratory strain EF3030 (Serotype 19F) was kindly provided by 
Dr. Marc Lipsitch, Boston, MA.  Laboratory strain ATCC6303 (Serotype 3) was obtained 
from ATCC, Manassas, VA. 
 
Clinical Isolates of S. pneumoniae 
Clinical isolates of S. pneumoniae were obtained from two main sources: 1) The 
Invasive Disease Surveillance Program (isolates are identified by a numerical prefix—ex. 
01); and 2) Nasopharyngeal sampling (isolates include either the BMS, ND, or LE prefix 
in their labels).  
The invasive disease samples were obtained from a population-based surveillance 
program for S. pneumoniae infection in children and started in Massachusetts in October 
2001.  The program was designed so that all clinical microbiology laboratories in 
Massachusetts would submit isolates of S. pneumoniae from the blood, cerebrospinal 
fluid or other normally sterile body sites collected form Massachusetts residents (18 years 
of age) to the Massachusetts Department of Public Health (MDPH).  The presence of S. 
pneumoniae was confirmed by optochin sensitivity and bile solubility by using standard 
microbiologic methods according to guidelines from the Clinical and Laboratory 
Standards Institute and serotyped by Quelling reaction (a biochemical reaction whereby 
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antibodies bind to the bacterial capsule) using pneumococcal antisera (Statens Serum 
Institute, Copenhagen, Denmark).  Isolates found to be unencapsulated were confirmed to 
be S. pneumoniae by lytA gene amplification by using real-time polymerase chain 
reaction.   
The nasopharyngeal carriage strains were obtained from nasopharyngeal swabs, 
which were taken from children at enrollment during well visits.  After collection, the 
swabs were placed in transport media (Starswab II™ Starplex Scientific Inc., Cleveland, 
TN) and refrigerated.  Specimens were delivered to the Boston Medical Center (BMC) 
Maxwell Finland Laboratory daily.  Swabs were then plated within 24-hrs of collection 
onto blood agar infused with gentamycin (Remel, Lenexa, KS), and incubated at 37°C in 
a candle jar for 18–24 hours.  S. pneumoniae isolates were identified based on alpha-
hemolysis, optochin disk susceptibility, and bile salt solubility testing.  Rough strains that 
demonstrated alpha-hemolysis were then selected for further characterization.  Serotype 
was determined by the Quelling reaction using serotype-specific pneumococcal antisera 
(Serum Statens Institute, Denmark) on pure isolate cultures.  Isolates were initially tested 
using grouped antisera followed by serial testing of serotypes within the positive group.  
Isolates suspected as being pneumococcus but non-typeable were confirmed by a 
fluorescent probe (Eurofins MWG Operon, Huntsville, AL).  
For use in experiments, all strains were cultured on blood agar plates (BD 
Biosciences) overnight while inverted in a humidified 37C 5% CO2 incubator.   Bacterial 
stocks were made by growing bacteria overnight on sheep blood agar plates (BD 
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Biosciences) and creating a thick bacterial suspension in Lysogeny Broth (LB) and 10% 
glycerol. Bacterial strains were stored at -80°C.   
 
MICE 
Mice lacking RelA in myeloid cells were generated by crossing LysM-Cre mice 
(Clausen et al., 1999) with Rela-floxed mice (Algul et al., 2007), generating a colony 
producing LysM-Cretg+/RelaloxP/loxP (RelAΔ/Δ) and LysM-Cretg-/ RelaloxP/loxP (RelAF/F) 
littermates. C57BL/6 mice (purchased from Jackson Labs) were maintained at the animal 
facility of the Boston University School of Medicine with free access to food and water.  
All animal experiments were approved by the facility’s Institutional Animal Care and 
Use Committee.   
 
CELL CULTURE 
Cell Line 
RAW 264.7 cells from the American Type Culture Collection (ATCC) were 
maintained in DMEM (Gibco) media containing 10% fetal bovine serum (FBS) and 
penicillin/streptomycin at 37°C in a humidified atmosphere containing 5% CO2.  
 
NF-κB Reporter Cell Line  
NF-κB reporter cells were created by stably transfecting RAW264.7 cells 
(ATCC) with a lentivirus construct containing firefly luciferase (driven by a minimal 
promoter and 4 tandem NFκB sites, so luminescence can report NF-κB-mediated gene 
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transcription) and GFP (driven by the Ubiquitin C promoter, so green fluorescence can be 
used as a marker of transduction) (Wilson et al., 2013). 
 
Sorting of GFP-expressing Live Cells for Subsequent Culture 
Transduced RAW 264.7 cells were pelleted after centrifugation for 5 min at 300 x 
g and 4°C followed by resuspension in 100 µl FACS buffer. Cells were sorted by 
Fluorescence Activated Cell Sorting (FACS) using a FACS Aria III (BD Biosciences) for 
positive GFP expression. Gating and compensation was performed using the auto-
compensation feature in the FACS Diva program used to operate the sorting machine.  
Single cells were sorted for clonal cell line development using the BD FACS Aria (set-up 
for single cell sorting).  Single cells were sorted from high GFP expressing cells and 
sorted into a 96 well plate containing DMEM complete medium under sterile, tissue 
culture conditions.  Single cells were then cultured at DMEM complete medium and then 
cultured at 37°C in a humidified atmosphere containing 5% CO2 and examined under a 
fluorescent microscope for successful clonal expansion and continued expression of GFP.  
 
HIGH-THROUGHPUT MACROPHAGE BIOASSAY 
Our NF-κB reporter cell lines were maintained in DMEM (Gibco) media 
containing 10% fetal bovine serum (FBS) and penicillin/streptomycin at 37°C in a 
humidified atmosphere containing 5% CO2. Cells were seeded at 7.5x105 cells/well and 
allowed to adhere overnight.  To stimulate cells, media was removed and fresh serum-
free and antibiotic-free DMEM media containing live S. pneumoniae at 107 colony 
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forming units (CFU)/well or other doses of bacteria (as specified) were added to wells for 
2 hours at 37°C in a humidified atmosphere containing 5% CO2.  Afterward, cells were 
washed with PBS and lysed. Lysates were made using Passive Lysis Buffer (Promega 
#E1941) according to manufacturer recommendations.  Luminescence was measured 
using a Luciferase Assay Protocol (Promega #E1501) on a Veritas Microplate 
Luminometer. Parallel wells with vehicle (assay media alone) or Lipopolysaccharide 
(LPS) from E. coli O111:B4 (InvivoGen #tlrl-3pelps) at 10ng/ml (LPS is known for its 
ability to activate NF-κB and to induce an immune response in our RAW264.7 cells) 
were included as negative and positive assay controls (respectively). All the 
pneumococcus data was normalized to the parallel LPS responses for each experiment.   
 
MOUSE MODEL OF PNEUMONIA 
Fifty microliters of saline containing S. pneumoniae EF3030, 6303, or patient-
derived clinical isolates were instilled into the left bronchus of 6–12-week-old mice via 
an intratracheal route of infection.  Mice were anesthetized by intraperitoneal injection of 
ketamine (50 mg/kg) and xylazine (5mg/kg).  The tracheas were then surgically exposed 
and cannulated using an angiocatheter directed to the left bronchus.  A bacterial 
suspension of S. pneumoniae suspended in sterile saline was then instilled intratracheally 
into the lungs, as previously described (Quinton et al., 2007).  
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ENDPOINT TISSUE COLLECTION 
Whole Lung  
At the indicated end-time points, mice were sacrificed and lung lobes were 
harvested and placed into Bullet Blender 5 ml tubes containing 10- 3.2 mm diameter 
stainless steel Bullet Blender beads (Next Advance) and 300 µl of 1x protease inhibitor 
(Roche #11849300) in sterile water. Following homogenization, lung homogenates were 
brought up to 5 ml with the 1x protease inhibitor solution.  Homogenates were then 
serially diluted in sterile water and plated on 5% sheep blood agar plates and incubated 
overnight at 37°C.  Colonies were counted on the following day.  Data were expressed as 
total CFU/lung.  
 
CYTOKINE PROTEIN MEASUREMENTS 
Cytokine protein concentrations were measured in whole-lung tissue homogenates 
(Quinton et al., 2008), using mouse TNF-α Duoset ELISA kit (R&D Systems #DY410) 
and mouse CXCL2 Duoset ELISA kit (R&D Systems #DY452). 
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IMMUNOFLUORESCENCE MICROSCOPY 
Detection of NF-κB p65 Nuclear Localization 
RAW 264.7 cells were seeded at 7.5x105 cells/well in 35-mm glass bottom culture 
dishes (Mat Tek) and allowed to adhere overnight.  The following day, cells were washed 
with 1X PBS and incubated with S. pneumoniae in serum-free, antibiotic-free, and phenol 
red free DMEM assay media at 37°C in a humidified atmosphere containing 5% CO2 for 
2-hrs. Thereafter, cells were washed three times with warm assay media and fixed in 
freshly prepared 4% paraformaldehyde in PBS for 20 min.  The fixed cells were then 
washed three times with PBS and then blocked for 1-hr in blocking buffer (3% BSA in 
PBS) at room temperature.  The NF-κB p65 rabbit polyclonal primary antibody (Santa 
Cruz #sc-372) was diluted (1:500) in 1%BSA/PBS and added to cells gently rocking 
overnight at 4°C.  The cells were then washed three times with PBS followed by a one-
hour incubation with fluorescein-conjugated secondary antibody (Life Technologies #A-
11008).  Phalloidin fluorescent dye (Biotium #00043-T) was used to stain actin and Dapi 
used to stain nuclei. Images were obtained with a Zeiss LSM 710-Live Duo scan 
microscope with 63X oil objective and processed using Image J software. 
 
Isolation of Primary Alveolar Macrophages from Bronchoalveolar Fluid 
Bronchalveolar lavage was performed 2-hrs post-infection.  Lungs were removed 
post mortem and trachea cannulated with a 20-gauge blunted stainless steel catheter.   A 
total volume of 10ml were collected by serial 1ml lavages with cold HBSS (no Ca2+ or 
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Mg2+) containing 1M HEPES, penicillin/streptomycin, and 0.5M EDTA.  The lavage 
fluid was centrifuged at 300xg for 5 minutes at 4°C. Cells were spun onto 
cytocentrifuged slides.  Thereafter, cells were fixed in freshly prepared 4% 
paraformaldehyde in PBS for 20 min.  The fixed cells were then washed three times with 
PBS and then blocked for 1-hr in blocking buffer (3% BSA in PBS) at room temperature.  
The NF-κB p65 rabbit polyclonal primary antibody (Santa Cruz #sc-372) was diluted 
(1:500) in 1%BSA/PBS and added to cells to incubate overnight at 4°C.  The cells were 
then washed three times with PBS followed by a one-hour incubation with fluorescein-
conjugated secondary antibody (Life Technologies #A-11008).  Phalloidin fluorescent 
dye (Biotium #00043-T) was used to stain actin and Dapi used to stain nuclei. Images 
were obtained with a Zeiss LSM 710-Live Duo scan microscope with 63X oil objective 
and processed using Image J software. 
LIVE-CELL IMAGING 
Cell Line 
RAW 264.7 cells were seeded at 7.5x105 cells/well in 35-mm glass bottom culture 
dishes (Mat Tek) and allowed to adhere overnight.  The following day, cells were washed 
with 1X PBS and incubated with S. pneumoniae in serum, antibiotic, and phenol red free 
DMEM assay media at 37°C in a humidified atmosphere containing 5% CO2 for 2-hrs.  
Thereafter, cells were washed once with warm assay media and stained with Hoechst 
(Life Technologies #33342) and Cell Mask Green plasma membrane stain (Life 
Technologies #C37608) according to manufacturer recommendations. Images were 
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obtained with a Zeiss LSM 710-Live Duo scan microscope with 63X oil objective.  
Images were process using Image J software. 
Primary Cells 
Naïve C57BL/6 mice were euthanized and bronchalveolar lavage performed. Lungs were 
removed post mortem and trachea cannulated with a 20-gauge blunted stainless steel 
catheter.  A total volume of 10ml were collected by serial 1ml lavages with cold HBSS 
(no Ca2+ or Mg2+) containing 1M HEPES, penicillin/streptomycin, and 0.5M EDTA.  The 
lavage fluid was centrifuged at 300xg for 5 minutes at 4°C. Cell pellets were resuspended 
in warm serum-free RPMI 1640 media and incubated at 37°C in a humidified atmosphere 
containing 5% CO2 for 1-hr to allow cells to adhere. Afterward, media was replaced with 
RPMI media containing 10% fetal bovine serum (FBS) and penicillin/streptomycin for 
overnight incubation.  The following day, cells were washed with PBS and incubated 
with S. pneumoniae in serum-free, antibiotic-free, and phenol red free DMEM assay 
media at 37°C in a humidified atmosphere containing 5% CO2 for 2-hrs.  Afterwards, 
cells were washed once with warm assay media and stained with Hoechst (Life 
Technologies #33342) and Cell Mask Green plasma membrane stain (Life Technologies 
#C37608) according to manufacturer recommendations. Images were obtained with a 
Zeiss LSM 710-Live Duo scan microscope with 63X oil objective.  Images were process 
using Image J software. 
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Cell Fluorescence   
ROS content was assessed using a CellROX Deep Red fluorogenic probe (Life 
Technologies #C10422) according to manufacturer recommendations.  RAW 264.7 cells 
were seeded at 7.5x105 cells/well in 35-mm glass bottom culture dishes (Mat Tek) and 
allowed to adhere overnight.  The following day, cells were washed with 1X PBS and 
incubated with CellROX Reagent in serum-free, antibiotic-free, and phenol red free 
DMEM assay media for 30 minutes.  Thereafter, cells were washed once with warm 
media and stained with Hoechst (Life Technologies #33342) and Cell Mask Green 
plasma membrane stain (Life Technologies #C37608) according to manufacturer 
recommendations.  Cells were then washed with warm assay media and placed in a 37° 
C, humidified atmosphere containing 5% CO2 imaging station chamber and treated with 
S. pneumoniae. Images were obtained with a Zeiss LSM 710-Live Duo scan microscope 
with 63X oil objective.  Time-lapse images were captured at 3-min intervals.  Bright 
fluorescence was assessed using Image J software.    
 
Plasma Membrane Permeability 
Cell viability was determined by detecting bright far-red fluorescent nuclei in 
cells treated with S. pneumoniae.  On day one, RAW 264.7 cells were cultured in 35-mm 
glass bottom culture dishes (Mat Tek).  On day two, cells were washed with PBS and 
incubated with S. pneumoniae in serum, antibiotic, and phenol red free DMEM assay 
media at 37°C in a humidified atmosphere containing 5% CO2 for 2-hrs.  Thereafter, cells 
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were washed once with warm assay media and stained with Hoechst (Life Technologies 
#33342), Cell Mask Green plasma membrane stain (Life Technologies #C37608), and 
NucRed Dead 647 Ready Probes Reagent (Molecular Probes #R37113) according to 
manufacturer recommendations.  Images were obtained with a Zeiss LSM 710-Live Duo 
scan microscope with 63X oil objective and processed using Image J software.  Bright 
far-red cells were considered dead cells.  
 
INHIBITION ASSAYS 
Cellular Oncosis 
Specific inhibition of RIP1 kinase by Necrostatin-1 in RAW 264.7 cells was 
achieved by evaluating cell morphology of cells treated with low NFκB activating S. 
pneumoniae cells pre-treated with NEC-1.  Cell morphology differences were detected 
using Cell Mask Green plasma membrane stain (Life Technologies #C37608) according 
to manufacturer recommendations. RAW 264.7 cells were seeded in 35-mm glass bottom 
culture dishes (Mat Tek) overnight at 37° C containing 5% CO2.  The following day, cells 
were washed once with warm assay media (phenol red-free, antibiotic-free, and serum-
free) and then treated with 10-4 M NEC-1 for 90 mins at 37° C. Following pre-treatment, 
cells were stimulated with S. pneumoniae for 2-hours.  Thereafter, cells were washed 
with warm media and stained with Hoechst (Life Technologies #33342) and Cell Mask 
Green plasma membrane stain (Life Technologies #C37608) according to manufacturer 
recommendations. Cells were placed in a 37°, humidified atmosphere containing 5% CO2 
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imaging station chamber for imaging. Images were obtained with a Zeiss LSM 710-Live 
Duo scan microscope with 63X oil objective.  Time-lapse images were captured at 3-min 
intervals.  Bright fluorescence was measured using Image J software.  
 
ROS Production 
Specific inhibition of RIP1 kinase by Necrostatin-1 in RAW 264.7 cells was 
achieved by observing ROS content of cells treated with low NFκB activating S. 
pneumoniae to NEC-1 pre-treated cells. ROS production was assessed using a CellROX 
Deep Red fluorogenic probe (Life Technologies #C10422) according to manufacturer 
recommendations.  RAW 264.7 cells were seeded in 35-mm glass bottom culture dishes 
(Mat Tek) overnight at 37° C containing 5% CO2.  The following day, cells were washed 
with PBS and incubated with CellROX Reagent in serum, antibiotic, and phenol red free 
DMEM assay media for 30 minutes.  Thereafter, cells were washed once with warm 
media and stained with Hoechst (Life Technologies #33342) and Cell Mask Green 
plasma membrane stain (Life Technologies #C37608) according to manufacturer 
recommendations.  Cells were then washed with warm assay media and treated with 10-4 
M NEC-1 for 90 mins.  Following pre-treatment, cells were placed in a 37°, humidified 
atmosphere containing 5% CO2 imaging station chamber and treated with S. pneumoniae. 
Images were obtained with a Zeiss LSM 710-Live Duo scan microscope with 63X oil 
objective.  Time-lapse images were captured at 3-min intervals.  Bright fluorescence was 
measured using Image J software.  
		
32 
COMMON BUFFERS AND REAGENTS 
CELL CULTURE 
Dulbecco’s Modified Eagle’s Medium (DMEM) Complete Media  
10% FBS and 1% Pen-Strep in DMEM (+ L-glutamine & phenol red) –Filter Sterilized 
 
HIGH-THROUGHPUT MACROPHAGE BIOASSAY 
Dulbecco’s Modified Eagle’s Medium (DMEM) Assay Media  
DMEM (+ L-glutamine & phenol red) no serum, no antibiotics –Filter Sterilized 
Cell Lysis Buffer 
Passive Lysis Buffer (Promega #E1941) 
 
ELISA 
Wash Buffer 
Phosphate buffered Saline (PBS) pH 7.4 + 0.05% Tween 20 (Sigma-Aldrich, #3563) 
Blocking Buffer 
5% BSA-PBS (Bovine Serum Albumin in Phosphate Buffered Saline) 
 
CONFOCAL MICROSCOPY 
Dulbecco’s Modified Eagle’s Medium (DMEM) Assay Media  
DMEM (+ L-glutamine & Sodium Pyruvate) no phenol red –Filter Sterilized 
Fixative 
4% Paraformaldehyde 
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Fluorescent dyes 
Table 3: Fluorescent Dyes Used for Live Cell Imaging 
FLUORESCENT 
DYE 
TARGET 
CELLULAR 
COMPONENT 
COMPANY & 
CATALOGUE # 
EXCITATION/EMISSION  INCUBATION 
TIME/TEMP°C 
CellMask Plasma 
Membrane 
Life 
Technologies, 
#C37608 
522/535 nm 10–15 mins at 
37°C 
CellRox Reactive 
Oxygen 
Species 
Life 
Technologies, 
#C10422 
644/665 nm 30 mins at 
37°C 
Dapi Nuclei Life 
Technologies, 
P-36941 
358/461 nm N/A 
Hoechst Nuclei Life 
Technologies, 
#33342 
350/461 nm 10–15 mins at 
37°C 
NucRed®Dead  DNA Life 
Technologies, 
R37113 
642/661 nm 15–30 mins at 
37°C 
Phalloidin  F-actin Biotium, 
#00043-T 
541/560 nm 20 mins at RT 
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MOUSE EXPERIMENTS 
Lavage Buffer for BAL Collection 
2.7 mM Ethylenediaminetetraacetic acid (EDTA), 20 mM 2-[4-(2-hydroxyethyl) 
piperazin-1-yl] ethanesulfonic Acid (HEPES), and 100 U/ml Penicillin-Streptomycin 
(Pen-Strep) in Hanks Balanced Salt Solution (HBSS) 
 
Protein Extraction Buffer 
25 mM Tris at pH 7.4, 50 mM Sodium Chloride, 0.5% Sodium Deoxycholate, 2% NP-40, 
0.2% Sodium Dodecyl Sulfate (SDS), and 1x Roche Complete Protease Inhibitor in 
deionized water 
 
IMMUNOBLOTTING 
Tris-Buffered Saline Tween (TBS-T) 
25 mM Tris at pH 8.0, 125 mM Sodium Chloride, 0.1% Tween-20 in deionized water 
Blocking Buffer 
5% Non-Fat Milk in Tris-Buffered Saline Tween (TSB-T) 
 
FLUORESCENCE-ACTIVATED CELL SORTING (FACS)  
Fluorescence-Activated Cell Sorting Buffer 
0.5% Fetal Bovine Serum (FBS) and 2 mM EDTA in PBS – Filter Sterilized 
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STATISTICAL ANALYSIS 
GraphPad Prism (GraphPad Software) was used for statistical analysis.  Data were 
presented as means +/- standard error.  Sets containing two groups of data were analyzed 
using 1-way ANOVA and a 2-tailed Mann-Whitney U test. Multiple comparisons 
amongst clinical isolates of S. pneumoniae were made using a Kruskal-Wallis with 
Dunn’s post hoc test or 1-way ANOVA with Newman-Keuls post hoc test. Differences 
were considered statistically significant if P < 0.05. 
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CHAPTER III: RESULTS 
RATIONALE 
Eliminating microbes from the lungs requires an intense inflammatory response 
(Mizgerd, 2006, Mizgerd, 2008). During pneumococcal pneumonia, alveolar macrophage 
NF-κB activation plays an important role in the induction of pro-inflammatory cytokine 
and chemokine production critical to anti-pneumococcal defense (Pittet et al., 2011). 
Furthermore, the literature also provides support for the role of the inflammatory 
response in determining the outcome of bacterial lung infections, such as pneumococcal 
pneumonia (Quinton and Mizgerd, 2015, Mizgerd, 2012, von Bernuth et al., 2008, van 
der Poll and Opal, 2009).  S. pneumoniae results in activation of NF-κB within the lungs 
(Quinton et al., 2007, van der Poll and Opal, 2009) but how pneumococci differ in their 
ability to specifically activate macrophage NF-κB has yet to be elucidated, especially as 
it relates to disease severity. In this study, we used distinct isolates of S. pneumoniae, a 
novel, high-throughput macrophage bioassay, and immunofluorescence confocal 
microscopy to comprehensively evaluate macrophage responses to pneumococcal 
stimulation.  The goal of this study is to better understand and define the host-pathogen 
interaction between pneumococcus and the alveolar macrophage as it relates to 
pneumococcal lung infection and severe pneumonia.   
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3.1. Differential Activation of Macrophage NF-κB by Isolates of Pneumococcus with 
Known Differences in Virulence 
To glean possible relationships between pneumococcus virulence and macrophage 
NF-κB activity, we compared 2 pneumococcal isolates commonly used in experiments, 
with clear differences in infection severity during mouse models of pneumonia.  We 
examined NF-κB activation in alveolar macrophages during the early stages of 
pneumonia by imaging NF-κB p65 nuclear accumulation in alveolar macrophages 
isolated from mice infected with S. pneumoniae strains 6303 or EF3030. The 6303 strain 
is extremely virulent in mice, a serotype 3 strain causing lethal pneumonia and 
bacteremia after even low dose infections (Quinton et al., 2009, Jones et al., 2005, 
Quinton et al., 2007, Arredouani et al., 2006, Tian et al., 2009, Dessing et al., 2007).  The 
EF3030 strain is less virulent, a serotype 19F strain causing self-limiting infections and 
no bacteremia in mice, even after infection with millions of CFU in the lungs (Briles et 
al., 2003, Jones et al., 2005, Quinton et al., 2007, Maus et al., 2007). Intracellular 
localization of p65 was visualized by immunofluorescence in macrophages lavaged from 
the lungs 2-hours after infection.  Alveolar macrophages from mice infected with EF3030 
showed greater NF-κB p65 protein translocation into the nucleus compared to the 
alveolar macrophages from mice infected with 6303 (Figure 1A).  We compared 
macrophage responses to these isolates in a more reductionist system, macrophage-like 
RAW264.7 cells stimulated in vitro with live pneumococcus.  As with primary alveolar 
macrophages collected from in vivo pneumonias, the cell lines stimulated by bacteria in 
vitro showed more pronounced NF-κB translocation from EF3030 than from 6303 
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(Figure 1B).  These data suggest that the more virulent isolate, 6303, activates 
macrophage NF-κB less than the better tolerated isolate, EF3030. 
  Difficulties with quantifying p65 nuclear translocation and the limited dynamic 
range of such a signal precluded the use of immunofluorescence for examining large 
numbers of community isolates of pneumococcus.  Therefore, we generated a 
macrophage NF-κB reporter cell by transducing RAW264.7 cells with a lentiviral vector 
in which expression of a luciferase transgene is driven by NF-κB (Wilson et al., 2013).  
For 5 different clonally derived cell lines, cells were cultured in 96 well plates and 
incubated with living pneumococcus for 2-hours, after which luminescence was 
measured using a plate-reading luminometer. Parallel wells were stimulated with LPS at 
a dose of 10 ng/ml as a positive control, and luciferase induction was expressed relative 
to this positive control from within the plate. The less virulent EF3030 isolate induced 
greater luminescence than did the more virulent 6303 strain of pneumococcus, throughout 
a wide dose-response range and across all 5 different clonal cell lines (Figure 2A). These 
results show that the cell lines report consistent differences in macrophage interactions 
with these 2 isolates of pneumococcus.  The dose-response curves revealed 107 CFU/ml 
or a MOI of ~10 to be well-suited to the assay system, which was used for all further 
studies of laboratory or community isolates and their interactions with macrophages.  At 
this dose, repeated independent experiments demonstrated that 6303 activated NF-κB 
significantly less than EF3030 (Figure 2B).  These data reveal that the assay system 
reveals reproducible differences in pneumococcal induced NF-κB activity in 
macrophages.  These results with laboratory isolates of pneumococcus support our 
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Figure 1. Differential Macrophage NF-κB Nuclear Translocation in Response to 
S. pneumoniae.  
(A) Confocal cytospin images of alveolar macrophages isolated after a 2-hr 
intratracheal lobar installation of EF3030 and ATCC6303 in C57BL/6 mice.  Presence 
of P65 is shown in green, F-actin is shown in red, and nuclei are shown in blue. Scale 
bar represents10µm.  Multiple cultures (n=2–3 mice/group) were examined. The 
experiment was conducted two independent times with the same result. 
(B) Differences in macrophage NF-κB activation in response to S. pneumoniae 
stimulation. Confocal images of RAW 264.7 cells after 2hr stimulation with EF3030 
laboratory isolate and ATCC6303 laboratory isolate.  P65 was detected by 
immunofluorescence using an NF-κB p65 antibody followed by a fluorescent dye 
conjugated secondary antibody. Scale bar represents 10µm.  The experiment was 
conducted two independent times with the same result. 
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Figure 2. S. pneumoniae Induces Divergent Macrophage NF-κB Activation 
(A) Macrophage NF-κB percent induction of 5 stably transduced RAW 264.7 cell lines 
after 2-hr stimulation with EF3030 (white squares) and ATCC6303 (black squares) at 
doses of 104, 105, 106, & 107 CFU/ml.  
(B) Macrophage NF-κB percent induction in RAW 264.7cells after 2-hr stimulation with 
EF3030 (white bar) and ATCC6303 (black bar) at a dose of 1x107 CFU/ml. 
P values were determined by Mann-Whitney U test  *p< 0.5.  Results in (B) are shown as 
mean + SEM. Experiments were performed at least three independent times with similar 
results. 
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hypothesis that low NF-κB activation is characteristic of more severe infections, and they 
provide direction for screening “real world” isolates of pneumococcus, collected from 
human volunteers and patients.  
	
3.2. Screening of Community Isolates of S. pneumoniae Reveals Heterogeneity in 
Macrophage NFκB Activation 
We have generated a biobank of pneumococcal isolates from children in the state 
of MA that can be used for analyzing pneumococcal variations that influence mammalian 
biology and human health.  A total of 105 different community isolates have been 
examined in the macrophage NF-κB screening assay.  Individual isolates of S. 
pneumoniae derived from human patients (with invasive pneumococcal disease) and 
volunteers (without pneumococcal disease) were screened using the macrophage bioassay 
to ascertain their distinct macrophage NF-κB activation levels.  A wide variety of 
macrophage NF-κB activity was triggered by the different isolates (Figure 3A).  NF-κB 
activation by pneumococcal isolates (Figure 3A) did not follow a normal distribution 
(Shapiro-Wilk test, P < 0.02), but instead the distribution tended to be skewed leftward 
(skewness = 0.39) and flattened (kurtosis = -0.41).  Thus, there is substantial variation in 
the ability to induce NF-κB activation amongst pneumococcal isolates in the community, 
and more isolates than predicted are low activators of macrophage NF-κB.  One 
determinant of virulence for pneumococcus is the capsular polysaccharides that separate 
them into >90 different serotypes (Kadioglu et al., 2008, Kalin, 1998, Martens et al., 
2004, Henriques-Normark and Tuomanen, 2013).  Therefore, we examined the 
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relationship between S. pneumoniae serotype and NF-κB activation in macrophages.  
There were significant differences amongst serotypes (P < 0.05, one-way ANOVA), but 
also a wide range of NF-κB activation within individual serotypes (Figure 3B).  Thus, 
there is a loose association between serotype and macrophage NF-κB activation, but 
serotype is not a major determinant of macrophage NF-κB activation.  
 
3.3. Low Macrophage NF-κB Activation Facilitates Bacterial Survival During 
Pneumococcal Pneumonia 
One of the most common manifestations of pneumococcal disease is pneumonia, 
which is likely due to virulence characteristics of the pneumococcus that increase its 
persistence within the lung (Kadioglu et al., 2008).  During the first 24 hours of 
pneumococcal pneumonia, TNF-α and IL-1 (α and β) cytokines are generated in the lungs 
and contribute to elimination of bacteria by host defenses (Jones et al., 2005, Quinton et 
al., 2009). Macrophage NF-κB RelA mediates this initial burst of early response 
cytokines, as well as the induction of CXCL2 to recruit neutrophils (Pittet et al., 2011). 
Based on screen results, which revealed pneumococci varying in their activation of 
macrophage NF-κB, it became of interest to determine whether those that activate less 
macrophage NF-κB are better able to survive and grow in the lungs.   
We first approached this question by examining relationships between the site of 
origin of the community isolates and their macrophage NF-κB activating propensity. 
Samples that were collected from pleural fluids were retrieved from patients with 
pneumonia complicated by empyema.  Samples from blood or CSF included patients 
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Figure 3. Heterogeneity in Macrophage NF-κB Activation Exists Amongst Clinical  
Isolates of S. pneumoniae.  
(A) Histogram of the frequency of macrophage NF-κB activation in community isolates 
of pneumococcus is displayed.   
(B) Relationship of macrophage NF-κB activation to serotype.  Macrophage NF-κB 
percent induction of stably transduced mouse macrophage-like RAW 264.7 cell line after 
2-hr stimulation with clinical isolates of pneumococcus at 107 CFU/ml. Each point 
represents a different pneumococcal isolate within the respective serotype.  Horizontal 
lines indicate median values. P values were determined by One-Way ANOVA (B) 
****p< 0.0001. 
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with a variety of pneumococcal diseases.  Samples labeled “carriage” were from the 
nasopharynx of children without pneumococcal disease.  The screen results revealed that 
pneumococcal isolates from the pleural fluid of empyema patients activated macrophage 
NF-κB less than pneumococci from the nasopharynx, blood, or cerebrospinal fluid 
(Figure 4).  While a wide variety of NF-κB activation was apparent in other sites, the 
isolates from pleural fluid consistently showed low NF-κB activation (Figure 4).  These 
data suggest that low NF-κB activation may be especially critical for pneumococcal 
survival in some settings, including but not necessarily limited to patients with 
complicated pneumonia.   
To directly compare the abilities of high and low NF-κB activating isolates of 
pneumococcus to survive within the lungs, we turned to an animal model (Mizgerd and 
Skerrett, 2008).  Isolates commonly used in animal models were consistent with the 
hypothesis in the sense that the more virulent 6303 isolate was a low NF-κB activator and 
the less virulent EF3030 a high NF-κB activator (Figure 2B).  Here, we test this concept 
with community isolates of pneumococcus.  We established lobar pneumonias in 
C57BL/6 mice with different clinical isolates of pneumococcus that were matched for 
serotype but differed in NF-κB activation.  Independent sets of experiments considered 
isolates from 2 different serotypes, 19A or 19F.  Mice were anesthetized and inoculated 
through the left bronchus with 1x107 colony-forming units (CFU) of pneumococcus.  
Local cytokine production was measured using ELISA, focusing on TNF-α and CXCL2 
since these are macrophage-derived and NF-κB-dependent during pneumococcal 
pneumonia (Pittet et al., 2011) .  For each of the serotypes examined, those isolates that 
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Figure 4. Relationship of Macrophage NF-κB Activation to Site of Origin. 
Graphical representation of macrophage NF-κB percent induction results grouped by 
known site of origin for serotypes (6A, 19A, 19F, 6C, 23A, 23B, 3, and 11A). Carriage 
denotes isolates taken from the nasopharynx of children without pneumococcal disease; 
Blood, pleural fluid, & CSF denotes isolates taken from patients with IPD; sputum 
denotes isolates taken from non-bacteremic pneumonia patients.  Each point represents a 
distinct pneumococcal isolate. Horizontal lines indicate median values. P values were 
determined by One-Way ANOVA ***p< 0.0005. 	
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activated less macrophage NF-κB in the screening assay triggered the expression of 
lower levels of macrophage-derived cytokines in infected lungs in vivo (Figure 5A & 
5C). To determine whether the variation in NF-κB activation and cytokine expression 
amongst the different clinical isolates influenced anti-pneumococcal lung defense, we 
measured bacterial survival in the infected lungs.  For each serotype, the isolates that 
better activated macrophage NF-κB in the in vitro screen (and were stronger inducers of 
macrophage-derived cytokines in vivo) were more readily eliminated from infected 
mouse lungs (Figure 5B & 5D).  These data support the hypothesis that avoiding or 
subverting macrophage NF-κB activation during acute pneumonia enhances S. 
pneumoniae survival in the lung.  
 
3.4. Low Activators of Macrophage NF-κB Trigger Altered Macrophage Responses 
It is conceivable that NF-κB activity is merely a marker of pneumococcal 
recognition.  If so, then low macrophage NF-κB activation would correlate with 
diminished activities of all macrophage responses.  Alternatively, since re-routing normal 
host defense cell signaling is a recognized method for some pathogens to circumvent a 
hostile host environment (Mogensen, 2009, Rosenberger and Finlay, 2003), it seems 
equally possible that virulent pneumococci do not simply avoid detection but instead 
push macrophages towards alternative pathways (and away from host-protective 
activities like NF-κB-mediated gene transcription).  To differentiate these possibilities, 
we investigated macrophage responses other than NF-κB to pneumococci with differing 
NF-κB activating profiles.  We used confocal microscopy to reveal how distinct isolates 
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Figure 5. Low Macrophage NF-κB Activation Facilitates Bacterial Survival in the 
Pneumonic Lung. 
(A,C) C57BL/6 mice were intratracheally inoculated with either high/low NF-κB 
activating serotype-matched pairs of S. pneumoniae patient isolates from serotype 19A 
(A) (07AR0013 & BMC0359C) or 19F (C) (09AR0014 & 03AR0122)  (n=5, per group). 
6-hrs post-infection mice were sacrificed and lungs harvested.  Lungs were homogenized 
and processed for protein measurements of: TNF- and CXCL2 cytokines. 
(B,D) C57BL/6 mice were intratracheally infected with either a high/low NF-κB 
activating serotype-matched pairs of S. pneumoniae patient isolates from serotype 19A or 
19F at 1x107 CFU (n=4–5, per group), and 15-hours post-inoculation mice were 
sacrificed and lung tissue were sampled for bacterial growth. P values were determined 
by One-way ANOVA and Mann-Whitney U tests (A & C). Results are shown as mean + 
SEM. *p< 0.5; **p<0.005; ****p< 0.0001.   
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influenced cell morphology and oxidative metabolism.  For RAW264.7 cells stimulated 
with EF3030, 6303, or clinical isolates of S. pneumoniae, the high and low NF-κB 
activating isolates caused consistently different changes in cell morphology (Figure 6A).  
The cells responding to high NF-κB activating isolates tended to become elongated and 
amoeboid compared to negative control cells without bacteria (Figure 6A).  In contrast, 
the macrophages stimulated with low NF-κB activators tended to become larger and 
rounder (Figure 6A).  For both the laboratory isolates and the clinical samples, cells 
stimulated with low NF-κB activator pneumococci produced more ROS than 
macrophages stimulated with high NF-κB activators (Figure 6B).  Live cell imaging 
revealed that the ROS generation preceded the cell swelling response (Figure 7).  These 
data refute the hypothesis that low NF-κB activators are stealth organisms that are not 
recognized by macrophages.  Instead, low NF-κB activators drive macrophages towards 
an alternate cell fate.   
 
3.5. The Alternate Macrophage Fate is Necroptosis 
Cell swelling and abundant ROS production are hallmarks of programmed 
necrosis, reflecting processes of cellular oncosis and energetic catastrophe (Pasparakis 
and Vandenabeele, 2015, Linkermann and Green, 2014, Christofferson and Yuan, 2010). 
Therefore, we sought to determine whether the altered macrophage response induced by 
low NF-κB activating isolates was directly coupled to cell death.   In addition to cellular 
rounding, swelling of an increasingly translucent cytoplasm, and ROS abundance, cells 
undergoing programmed necrosis are defined by their loss of plasma membrane integrity 
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Figure 6. Low NF-κB Activating Pneumococci Trigger Cellular Oncosis and 
Excessive ROS Production in Macrophages. 
A) Oncosis in RAW 264.7 cells develops in response to stimulation with low NF-κB 
activating S. pneumoniae.  Effects of NF-κB activation on plasma membrane morphology 
after 2-hr stimulation with: EF303 & ATCC6303 (laboratory isolates) and 07AR0013 & 
BMC0359C (HIGH/LOW clinical isolates, respectively) were analyzed by confocal 
microscopy using a fluorescent plasma membrane dye (CellMask green). Scale bars represent 
10µm.  The experiment was conducted at least three independent times with the same result. 
(B) Increased reactive oxygen species (ROS) production in RAW 264.7 cells in response to 
low NF-κB activation S. pneumoniae stimulation. Effects of NF-κB activation on ROS 
production after S. pneumoniae stimulation with: EF303 & 6303 (laboratory isolates) and 
07AR0013 & BMC0359C (HIGH/LOW NF-κB activating clinical isolates, respectively) was 
analyzed by confocal microscopy using a fluorescent CellROX Oxidative Stress Reagent dye. 
Scale bars represent 10µm.  The experiment was conducted at least three independent times 
with the similar results. 
(C) Quantification of relative frequency of cellular oncosis in RAW 264.7 cells in response to 
stimulation with high and low NF-κB activating lab and clinical isolates of S. pneumoniae. 
(D) Quantification of the relative frequency of fluorescent cells after stimulation with S. 
pneumoniae. RAW264.7 cells were stained with CellROX Oxidative Stress fluorescent dye. 
P values were determined by One-way ANOVA and Mann-Whitney U tests (C & D).  
Results are shown as mean + SEM. ****p<0.0001, ***p<0.001, **p<0.005, *p<0.05.	
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Figure 7. Low NF-κB Activating S. pneumoniae Causes Morphological Changes 
Indicative of Necroptosis.  
Time-lapse experiment done in RAW 264.7 cells to illustrate the progression of oncosis 
development and ROS production during the course of macrophage stimulation. Effects 
of NF-κB activation on plasma membrane morphology and ROS production during 
stimulation with 6303 (laboratory isolates) using fluorescent plasma membrane dye 
(CellMask green) and reactive oxygen species dye (CELL ROX).  	
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(Berghe et al., 2010, Vandenabeele et al., 2010, Pasparakis and Vandenabeele, 2015).  
Macrophage-like RAW264.7 cells were stimulated with low or high NF-κB activator S. 
pneumoniae or vehicle, and nuclear staining from a membrane impermeable far-red 
fluorescent dye was measured after 2 hours of co-culture.  Cells stimulated with low NF-
κB activators showed increased plasma membrane permeability and nuclear staining by 
the vital dye, whereas co-culture with high NF-κB activating pneumococci did not 
(Figure 8A).  Thus, low NF-κB activators increase membrane permeability in 
conjunction with cellular oncosis and excess ROS production, indicative of programmed 
necrosis (Pasparakis and Vandenabeele, 2015).   
Cell lines can have peculiarities relating to cell death pathways, so we tested 
whether primary alveolar macrophages responded disparately to the divergent phenotypes 
of pneumococcus.  Cultures of primary macrophages lavaged from the lungs of healthy 
mice were cultured with low NF-κB activator or high NF-κB activator pneumococci.  
Primary macrophages responded to the high NF-κB activator but not the low NF-κB 
activator with cellular oncosis (Figure 8B), demonstrating that these divergent responses 
apply directly to the alveolar macrophages that patrol the surfaces of the lung.   
Discrete pathways of programmed necrosis are distinguished by different 
molecular mechanisms that result in the common outcomes that have been observed with 
low but not high NF-κB activating pneumococci. Furthermore, the RIPK1 inhibitor Nec-
1 was capable of completely preventing both ROS production (Figure 9C) and cellular 
oncosis (Figure 9A) induced by low NF-κB activating pneumococci. These results  
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Figure 8. Low NF-κB Activation Compromises Plasma Membrane Integrity in 
Macrophages. 
(A) Determining cell viability of macrophages after a 2-hr pneumococcal stimulation 
with EF3030 and 3030 laboratory strains. Bright far-red fluorescent nuclei in cells after 
2-hr treatment with S. pneumoniae was assessed using NucRed Dead stain.  Cells also 
stained with Hoechst nuclei stain and Cell Mask Green plasma membrane stain. Bright 
far-red cells were considered dead cells. 
(B) Quantification of relative frequency of dead cells after stimulation with high and low 
NF-κB activating lab and clinical isolates of S. pneumoniae.  
(C) Alveolar macrophages obtained from naïve C57 BL/6 mice by Bronchoalveolar 
lavage were stained with Cell Mask plasma membrane stain and Hoechst nuclei stain to 
detect the occurrence of cellular oncosis in primary cells. Scale bars represent 10µm.   
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Figure 9. Inhibition of Cellular Oncosis and Excessive ROS production in 
Macrophages. 
(A) Specific inhibition of cellular oncosis using the RIP1 kinase inhibitor Necrostatin-1 
(NEC-1). RAW 264.7 cells pre-treated with NEC-1 for 90-mins and imaged to evaluate 
cell morphology changes in macrophages after pneumococcal stimulation with 6303 low 
NF-κB activating laboratory isolate. 
(B) Quantification of relative frequency of cellular oncosis in RAW 264.7 cells in 
response to stimulation with 6303 low NF-κB activating lab isolates and cells stimulated 
with 6303 after pre-treatment with NEC-1.  
(C) Specific inhibition of excessive ROS production using NEC-1. RAW 264.7 cells pre-
treated with NEC-1 for 90-mins and imaged to evaluate differences in ROS production in 
macrophages after pneumococcal stimulation with 6303 low NF-κB activating laboratory 
isolate.  Scale bars represent 10 µm. Images were obtained with a Zeiss LSM 710-Live 
Duo scan microscope with 63X oil objective. 
(D) Quantification of the relative frequency of fluorescent cells. RAW264.7 cells were 
stimulated with S. pneumoniae lab isolate 6303 or 6303 after pre-treatment with NEC-1.  
P values were determined by Mann-Whitney U test (B).  Results are shown as mean + 
SEM. ****p<0.0001. 
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reveal that the altered macrophage responses elicited by low NF-κB activators reflect 
pneumococcal induction of necroptosis. 
 
3.6. Appropriate Macrophage Activation Can Prevent 
Necroptosis and Severe Pneumonia 
The above results suggest that different pneumococci can drive macrophages 
towards either of 2 cell fates: NF-κB-mediated gene expression (which drives cytokine 
production to orchestrate effective immunity that rapidly eliminates bacteria from the 
lungs) or necroptosis (with less NF-κB activation and resulting in more severe infection).  
It is of translational significance to consider whether macrophage responses to the latter 
(more virulent) phenotype of pneumococci can be converted to the former protective 
activities.  Therefore, we designed a series of in vitro co-stimulation and in vivo co-
infection experiments to test whether macrophage necroptosis and lung infection caused 
by low NF-κB activators could be reversed and improved by an excess of high NF-κB 
activators.  Macrophage-like cells were cultured in vitro with a low NF-κB activating 
pneumococcus (6303) or with that same dose of 6303 plus an excess of high NF-κB 
activating pneumococcus (EF3030).  Intriguingly, the presence of the EF3030 (high NF-
κB) strain prevented the morphological changes caused by the 6303 (low NF-κB) strain 
(Figure 10A).  These data demonstrate that the high NF-κB activator pneumococci can 
stimulate pathways that overcome the deleterious necroptosis pathways elicited by the 
low NF-κB activator.   
To determine whether such protection might apply in vivo during a lung infection, 
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mice received intratracheal inoculations with S. pneumoniae strains 6303 (low NF-κB) 
alone, or that same dose of 6303 (low NF-κB) with an excess of EF3030 (high NF-κB).  
CFU were enumerated in homogenates from lungs harvested 48 hours after infection.  
Mice which received 6303 (low NF-κB)	alone experienced severe infections, with 
bacterial burdens in the lung approaching a thousand-fold the infecting dose (Figure 
10C).  In contrast, the lungs of mice that received the same dose of 6303 (low NF-κB) 
but also an excess of EF3030 (high NF-κB) had reduced CFU, a hundred-fold less than 
the original infecting dose (Figure 10C).  Thus, the presence of EF3030 (high NF-κB) 
enhanced host defense and elimination of 6303 (low NF-κB) from the lungs, 
demonstrating that a high NF-κB activator could protect in vivo against severe 
pneumonia caused by a necroptosis inducer.  We tested whether macrophage NF-κB was 
essential to this protection using mice with a targeted mutation of NF-κB p65 in myeloid 
cells including alveolar macrophages (Pittet et al., 2011).  In contrast to wild type mice, 
the presence of high NF-κB activator pneumococci (EF3030) was incapable of enhancing 
host defense against low NF-κB activator pneumococci (6303) in the lungs of mice 
whose alveolar macrophages lacked NF-κB p65 (Figure 10D). Therefore, the ability of 
the less virulent strain of S. pneumoniae to provide defense against the more virulent 
strain was entirely dependent on macrophage NF-κB.  These data suggest that 
appropriate macrophage activation involving NF-κB p65 can enhance the elimination of 
an otherwise highly virulent necroptosis-inducing isolate of S. pneumoniae during lung 
infection.	
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Figure 10. Induction of High NF-κB Activation Rescues Macrophages from 
Necroptosis and Lungs from Pneumonia.  
(A) High NF-κB activation rescues macrophages from oncosis.  Co-stimulation of RAW 
264.7 cells with (ATCC6303 and EF3030 combined). Effects of S. pneumoniae co-
stimulation on cell morphology was visualized using CellMASK green plasma membrane 
statin. Scale bars, 10µm. Experiments were repeated three independent times with the 
same result. 
(B) Quantification of relative frequency of cellular oncosis in RAW 264.7 cells in 
response to stimulation with EF3030 (high), 6303 (low) NF-κB activating isolates, and in 
combination. 
(C) Enhanced lung bacterial clearance 48 hrs after co-infection in C57BL/6 mice. Mice 
were infected with a bacterial suspension of 6303 and a bacterial suspension consisting of 
a combination of both 6303+EF3030.  Mice were infected with 105 CFU of 6303 or 105 
CFU of 6303 + 106 CFU of EF3030 via intratracheal instillation. Y-axis is CFU/Lung of 
low isolate. 48-hrs post-infection mice were sacrificed and lungs harvested.  Lungs were 
homogenized and lung tissue sampled for bacterial growth. 
(D) Bacterial clearance impaired by macrophage NF-κB deficiency. 48-hour co-infection 
in mice lacking macrophage NF-κB RelA due to gene targeting (floxed Rela and LysM-
Cre). Mice were infected with 105 CFU of 6303 or 105 CFU of 6303 + 106 CFU of 
EF3030 via intratracheal instillation. Y-axis is CFU/Lung of low isolate. 48-hrs post-
infection the mice were sacrificed and lungs harvested.  Lungs were homogenized and 
lung tissue sampled for bacterial growth.  P values were determined by One-Way 
ANOVA (B) and Mann-Whitney U tests (B,C,D).  Results in (B, C, & D) are shown as 
mean + SEM. ****p<0.0001, **p< 0.005, n.s., not significant.  
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CHAPTER V: DISCUSSION	
 
Overview: A Summary of Main Results  
In this study we investigated macrophage-pneumococcal interactions during acute 
lower respiratory tract infections in order to better understand how differences in 
macrophage NF-κB activation by S. pneumoniae influenced anti-pneumococcal lung-
specific host resistance.  We provide evidence which shows that pneumococcal 
interactions with macrophages are highly variable and a critical determinant of infection 
severity. In addition, we show that activation of the alveolar macrophage NFκB signaling 
pathway is essential to pneumococcal resistance and clearance by trigging an effective 
pro-inflammatory response against pneumococcus in the lungs. Lastly, our studies that 
focus on cell morphology, ROS production, and membrane permeability show that low 
NF-κB activation leads to a skewed alveolar macrophage response of cell death by 
necroptosis and more severe infection. These results underscore the damaging role of 
virulent, low NF- κB activating isolates of S. pneumoniae during pneumonia and point to 
a novel virulence pathway for pneumococci.  
 
Avoiding Macrophage NF-κB Activation: Extending Our Knowledge of  
Pneumococcal Virulence 
The alveolar macrophage is a critical innate immune barrier to bacterial 
pneumonia and plays a crucial role in triggering a pro-inflammatory response against S. 
pneumoniae in the lungs (Pittet et al., 2011, Aronoff et al., 2012, Hess et al., 2010). Our 
		
58 
investigation of macrophage-pneumococcal interactions began with gaining an 
appreciation for the diversity that exists among community isolates of pneumococcus in 
their ability to activate macrophage NF-κB and trigger an effective immune response. 
Our initial studies across many isolates of pneumococcus revealed heterogeneity in 
macrophage NF-κB activation, even within a given serotype.  Furthermore, in vivo mouse 
experiments that established lobar pneumonias with either high or low NF-κB activating 
isolates of S. pneumoniae showed that effective clearance of pneumococcus was 
enhanced by a strong induction of macrophage NFκB activation. Co-infection studies 
using C57BL/6 mice infected with a combined bacterial suspension of both a low and 
high NF-κB activating isolates also provided evidence to support the notion that 
enhanced host defense could rescue mice from severe, life-threatening pneumonia. All of 
these data provided support for the critical role of efficient macrophage NF-κB activation 
in resistance and clearance of pneumococcus from the lungs.  Interestingly, these data 
also provided evidence to support the premise that subversion of alveolar macrophage 
NF-κB activity is a plausible mechanism for pneumococci to secure infection.   
Why do pneumococci that activate less NF-κB survive better in the lung?  NF-κB 
is critical to many innate immune responses (Alcamo et al., 2001, Quinton et al., 2007), 
and pathogen survival in hostile environments such as the infected lung depends on an 
ability to thwart key immune responses (Rosenberger and Finlay, 2003). So a likely 
factor is that anti-bacterial innate immunity is diminished for these isolates.  
Macrophage-specific pro-inflammatory cytokines and chemokines levels were 
diminished in mice infected with low NF-κB activator isolates, in comparison to others 
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infected with high NF-κB activators.  These macrophage cytokines are essential to 
effective lung defense against bacteria (Pittet et al., 2011, Hess et al., 2010); hence their 
diminished expression likely enables better bacterial survival and growth of low NF-κB 
activator pneumococci in the air spaces.   
Diminished expression of cytokines may not be the only detriment in host 
immunity for low NF-κB activators.  Scrutiny of cell morphology, ROS production, and 
plasma membrane permeability revealed evidence of programmed necrosis in 
macrophages stimulated with low NF-κB activating isolates.  Macrophages have many 
roles in lung defense (Prince, 2013, Quinton and Mizgerd, 2015), such as sensing 
microbial particles by detecting PAMPs and activating pro-inflammatory signaling 
(Ozinsky et al., 2000), phagocytosing and killing bacteria (Aberdein et al., 2013, 
Flannagan et al., 2012), and eliminating dead and dying leukocytes through efferocytosis 
(Martin et al., 2012).  Thus, loss of this critical immune cell population may further 
contribute to the enhanced survival of low NF-κB activating pneumococci.  In addition to 
minimizing expression of host defense cytokines, inducing macrophage programmed cell 
death is another plausible mechanism for pneumococci to secure infection.   
 
Necroptosis: Contributions to Host-Microbe Interactions  
The term programmed cell death is defined as a regulated form of cell death 
mediated by an intracellular program (Christofferson et al., 2014).  Apoptosis, a form of 
programmed cell death mediated by caspases, (Ellis and Horvitz, 1986) was the first 
evolutionarily conserved cellular death pathway discovered (Kerr et al., 1972, Kerr, 
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2002) and for many years thought to be the only form of programmed cell death.  
However, in recent years, our understanding of programmed cell death has been extended 
to include other regulated forms of cell death, such as necroptosis (Linkermann and 
Green, 2014, Christofferson and Yuan, 2010). Necroptosis is a specific pathway of cell 
death by programmed necrosis (Pasparakis and Vandenabeele, 2015, Christofferson and 
Yuan, 2010). Morphological features of cell death play an important role in 
distinguishing necroptosis from apoptosis.  The known features that characterize 
apoptotic cells are exposure of phosphatidylserine on the outer plasma membrane, 
nuclear condensation and fragmentation, cell body shrinkage, and cytoplasmic membrane 
blebbing that does not disrupt membrane integrity (Alberts et al., 2002). In contrast, cells 
undergoing necroptosis are characterized by cellular rounding, cytoplasmic swelling 
(oncosis), increasingly translucent cytoplasm, and loss of plasma membrane integrity 
(Berghe et al., 2010, Vandenabeele et al., 2010).   Our results from confocal microscopy 
studies that showed cell swelling and abundant ROS production (hallmarks of 
programmed necrosis), revealed an altered macrophage response elicited by low NF-κB 
activators. Therefore, we interpreted these data as evidence showing that this altered 
response reflected pneumococcal induction of necroptosis. 
An appreciation for the specific role of necroptosis in microbial infections has 
increased greatly over the past decade.  The study of host-pathogen interactions now 
includes many efforts to elucidate the highly complex role of necroptosis in pathogen 
virulence mechanisms and host defense responses (Robinson et al., 2012, Kitur et al., 
2015, Huang et al., 2015). Our understanding of the benefits of some host-pathogen 
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interactions is that microbial pathogens may improve their ability to persist in infected 
hosts (such as in the lungs) by causing the death of cells essential for host defense (Fink 
and Cookson, 2005).  For example, recent studies focused on a virulent strain of 
staphylococcus aureus, known for causing inflammatory necrotizing pneumonia, have 
provided strong evidence supporting the role of necroptosis in alveolar macrophage 
depletion and the development of lung disease (Kitur et al., 2015). Results from our S. 
pneumoniae studies investigating the effect of NF-κB activation on cell morphology, 
ROS production, and membrane permeability suggest that low NF-κB activating isolates 
of pneumococcus are more virulent during pneumonia due to their propensity to cause 
cell death in alveolar macrophages and persist in the pneumonic lung.  
To date, very little is known about S. pneumoniae and its tendency to induce 
programmed necrosis in macrophages. Studies have shown that pneumococci can cause 
macrophage apoptosis-associated killing to help eliminate ingested bacteria (Aberdein et 
al., 2013) but no studies to our knowledge show a potential role for necroptosis in 
pneumococcal virulence. Our study results, which showed that some of our 
pneumococcal isolates could induce necroptosis to secure infection, provide insight into a 
specific and novel area of macrophage-pneumococcal interaction that could help to 
discern the molecular mechanisms underlying severity of pneumococcal pneumonia and 
lung disease.  
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Study Limitations 
Our results showing cellular oncosis, high ROS, and membrane permeability 
implicated an altered macrophage response of programmed necrosis (necroptosis). 
However, it should be noted that there are additional modes of programmed necrosis such 
as pyroptosis, ferroptosis, parthanatos and mitochondrial permeability transition 
(Pasparakis and Vandenabeele, 2015, Linkermann and Green, 2014, Christofferson et al., 
2014) but what led our focus on necroptosis were the results obtained from our studies 
with Necrostatin-1 (NEC-1) a specific inhibitor of RIPK1 activity and necroptosis.  
Necroptosis, but not other programmed necrosis pathways, requires RIPK1 activity and is 
inhibited by NEC-1 (Pasparakis and Vandenabeele, 2015). In our studies, we found that 
NEC-1 completely prevented oncosis in our macrophage cultures with the low NF-κB 
activating isolate of pneumococcus, strongly supporting the hypothesis that necroptosis 
was induced.  However, our study lacks the evidence of molecular mechanisms uniquely 
associated with necroptosis and this limits our ability to go beyond a strong assumption 
of necroptosis with absolute certainty.  Studies to obtain evidence of intracellular 
assembly of the necrosome (a complex that acts as the transducer of the necroptotic 
signal) composed of core components: receptor-interacting protein kinase 1 (RIPK1) and 
RIPK3 (Linkermann and Green, 2014) and the mixed linage kinase domain-like (MLKL) 
protein downstream of RIPK3 (involved in the execution of necroptosis) (Pasparakis and 
Vandenabeele, 2015, Linkermann and Green, 2014, Christofferson et al., 2014) would 
inform our understanding of the molecular pathway driving the observed necrosis 
phenotype seen in our macrophages. Furthermore, gaining a better understanding of the 
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different signaling components of the necroptosis cascade would help to determine 
portions of the pathway that could be targeted to prevent pneumococcal induction of 
necroptosis and lung damage.  
To date, TNF is one the most extensively studies extracellular signals that can 
lead to necroptosis.  However, a number of other signals (such as microbial factors) have 
also been identified as being able to trigger necroptosis (Han et al., 2011). Bacterial 
products such as lipopolysaccharide (LPS) (Ma et al., 2005), cholesterol-dependent 
cytolysin (CDC) (LaRocca et al., 2014), and Hla (a major agr-dependent staphylococcal 
toxin) (Kitur et al., 2015) have all been shown to cause cell death by necroptosis in 
different host cells. Our study results indicate that some pneumococci (low NF-κB 
activating) induce necroptosis in alveolar macrophages.  However, we have yet to 
identify the specific pneumococcal factor that is responsible for mediating necroptosis. 
Without a solid grasp on a particular microbial factor, our study of pneumococcal-
macrophage interactions in the context of pneumonia severity will be limited.  
Understanding how necroptosis is induced during pneumococcal lung infection would 
empower our ability to target specific signaling pathways of the pneumococcal-
macrophage interaction during pneumococcal pneumonia.  
Throughout our study we provided evidence, which showed that pneumococcal 
interactions with macrophages are highly variable and a critical determinant of infection 
severity; and that low NF-κB activation leads to a skewed alveolar macrophage response 
of cell death by necroptosis and more severe infection. These conclusions were drawn 
from a range of in vitro and in vivo experiments conducted in mouse cell lines 
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(RAW264.7 cells), mouse primary cells (alveolar macrophages derived from 
bronchoalveolar lavage fluid), and live mice. At this study’s inception, the decision to use 
a mouse cell line was based on the forethought of eventually wanting to test our in vitro 
results in a compatible, live organism to achieve biologically relevant in vitro and in vivo 
modeling.  S. pneumoniae is a human pathogen therefore the use of humans would be the 
most biologically relevant. However, the use of humans as a model system for pathogens 
is not possible due to safety, ethical and expense related concerns. Animal 
experimentation (especially in inbred mice) has been a viable alternative and an essential 
tool to study the pathogenesis of infectious disease due to: 1) the presence of a tightly 
controlled immune system that allows for more uniform responses to experimental 
treatments; 2) the animal’s small size; 3) the animal’s rapid reproductive rate; 4) and the 
ability to reproduce data in large numbers (Chiavolini et al., 2008). The mouse model is 
one of the most commonly employed systems for the characterization of lower 
respiratory tract infections (Chiavolini et al., 2008, Mizgerd and Skerrett, 2008). In 
particular, the study of pneumonia due to S. pneumoniae has been studied heavily in the 
mouse and has proven useful in assessing pathology and disease severity (Mizgerd and 
Skerrett, 2008). However, it cannot be ignored that S. pneumoniae is a human pathogen 
that lacks an environmental reservoir (Weiser, 2010, van der Poll and Opal, 2009, 
Bogaert et al., 2004).  Therefore, a limitation does present itself in the fact that our 
studies did not include testing of our pneumococcal isolates in any human derived cells 
(culture or primary cells). Human cells could differ greatly from animal cells in surface 
receptor expression or molecular phenotype for example and these differences could 
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account for significant differences in overall disease phenotype.  Therefore testing our 
isolates in human derived cells would be an important future, next step that would allow 
us to make more concrete conclusions about the potential effects of especially virulent 
community isolates of S. pneumoniae during pneumonia.    
 
Future Directions 
Our studies uncover an interesting host-microbe interaction that illustrates the 
damaging role of virulent, low NF-κB activating isolates of S. pneumoniae during 
pneumonia and furthermore suggest an unrecognized virulence pathway for 
pneumococci. Our in vivo study results suggested that low NF-κB activators were more 
virulent because they elicited less immune defense and enhanced bacterial survival by 
inducing necroptosis in alveolar macrophages.  Future directions should focus on 
identifying the molecular players involved in the induction and execution of necroptosis.  
As discussed earlier, necroptosis is an area of intense study during host-microbe 
interactions. However, questions such as whether or not necrosomal formation is induced 
during stimulation with the low NF-κB activating isolates still remains unclear.  
Furthermore, if necrosome formation is involved in the cell death observed in the alveolar 
macrophages, what are the mechanisms that control the formation of the necrosome 
during pneumococcal pneumonia.   
To assess necrosome formation, cultures of RAW264.7 cells can be stimulated 
with a low NF-κB activating isolate of S. pneumoniae that has been shown to induce 
cellular oncosis.  Protein lysates could then be collected and used to perform co-
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immunoprecipitation experiments using RIP1 and RIP3 specific antibodies.  
Immunoblots could then be used to test if RIP1, RIP3, and MLKL (necrosome complex 
proteins) would be pulled down together.  Co-precipitation of the necrosome components 
(RIP1, RIP3, and MLKL) would provide evidence of the necrosome.  To assess the 
functional role of the necrosome components, we could knock-down RIP1, RIP3, or 
MLKL using siRNA in RAW264.7 cells.  Using confocal microscopy, we could then 
stimulate our cells with NF-κB activating S. pneumoniae and observe for the occurrence 
of cellular oncosis. A decreased prevalence of cellular oncosis in the siRNA treated 
cultures would show that inhibition of necroptosis due to the knock-down of necrosomal 
components (RIP1, RIP3, MLKL) would support the notion that these components are 
essential for the macrophage cell death seen in the macrophages stimulated with low NF-
κB activating pneumococci.   
Within the last few years, necroptosis has been associated with a number of 
disease conditions, such as: atherosclerosis (Lin et al., 2013), neurodegenerative diseases 
(Liu et al., 2015), pancreatitis (He et al., 2009) photoreceptor cell loss (Trichonas et al., 
2010), and ischemia-reperfusion damage (Linkermann et al., 2012, Oerlemans et al., 
2012); and it is an area of intense investigation due to its promise for therapeutic 
approaches. The observation that pneumococci that are low NF-κB activators induce 
detrimental necroptosis responses in macrophage-pneumococcus interactions and that the 
RIP1-inhibitor, Necrostatin-1 prevents macrophage necrosis in cell culture suggests that 
in vivo testing of necroptosis inhibitors and/or mutant mice lacking specific necrosome 
components (such as RIP3 or MLKL) should be tested to discern whether inhibitors of 
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the necrosome could improve pneumonia outcome.   
 Additional future directions would be to identify potential microbial factors of the 
virulent pneumococci responsible for inducing necroptosis in the alveolar macrophages. 
Gaining a better understanding of the attributing factors responsible for the destructive 
effects seen in cell culture to alveolar macrophages could identify plausible targets for 
drug development that could reverse the detrimental effects of necroptosis. Preliminary 
studies that looked at cyclic-AMP provide support for further investigation of this 
microbial product in connection with pneumococcal virulence.  As discussed previously, 
necroptosis occurs through morphologically distinct processes.  Live cell confocal 
microscopy is a useful technique that allows cells to be observed as they undergo changes 
and would be an effective method to use to visual the effect of cyclic-AMP on cell 
morphology to discern whether it plays a role in the induction of necroptosis.     
 
Future Translational Potential: Applications Toward the Development of New 
Treatments for Pneumococcal Pneumonia 
The pneumococcus has an impressive history and has proven to be a formidable 
pathogen in infectious disease studies.  Still today, it is estimated that in the US, 
approximately 5% of individuals that get pneumococcal pneumonia will die from the 
infection (Cevey-Macherel et al., 2009).   
The work presented in this thesis served to add to the body of scientific 
knowledge about pneumococcal pneumonia by elucidating a novel virulence 
characteristic of some isolates of S. pneumonia (specifically those that were identified as 
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low NF-κB activating).  We propose that the definition of virulence, in the context of 
pneumococcal pneumonia, be extended to include macrophage responses. Our results 
from co-infection studies showed that the deleterious effects of the low NF-κB activating 
isolate were successfully reversed by the induction of a robust activation of NF-κB.  We 
believe measures to synthetically induce such an appropriate macrophage response, 
which requires but may not be limited to NF-κB activation, would be a plausible 
approach to providing protection against lung infection by virulent pneumococci.  In 
addition, our study results highlight the potential for developing novel approaches to 
fighting pneumococcal lung infection by interrupting the low NF-κB activating 
pneumococcal isolate virulence pathways, using vaccines based on effector molecules of 
the necroptosis pathway or drugs that target components of this pathway.  
Overall, it is believed that in order to move forward in reducing the disease 
burden of pneumonia, future studies will need to simultaneously analyze the microbe and 
host variables involved in disease progression and resistance.  As we have shown in our 
studies, damage to host cells was a measurable parameter that we were empowered to 
recognize through careful investigation of both the alveolar macrophage and 
pneumococcus during a very specific host-microbe interaction.   
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APPENDIX 
APPENDIX 1: DEVELOPMENT OF CLONAL CELL LINES 
 
As discussed previously, in order to compare NF-κB activation by different 
pneumococcal isolates, we developed a high throughput cell reporter system.  In short, 
we transduced the mouse macrophage-like RAW264.7 cell line with a lentivirus in which 
(1) firefly luciferase is driven by a minimal promoter and 4 tandem NF-κB sites, so 
luminescence can report NF-κB-mediated gene transcription, and (2) GFP is driven by 
the Ubiquitin C promoter, so green fluorescence can be used as a marker of transduction.  
Initially, these cells were sorted for GFP+ cells to generate an oligoclonal cell population 
and preliminary results obtained using these cells allowed us to detect differences in 
macrophage NF-κB activation amongst different isolates of S. pneumoniae (Figure A1.1).  
These oligoclonal cells were cultured and regularly observed for GRP expression by 
fluorescence microscopy to monitor transduction efficiency.  Interestingly, it was later 
noticed that with successive passages, the GFP expression in our cells began to diminish 
(Figure A1.2).   After many trials of trouble-shooting, it was hypothesized that the GFP 
expressing cells were being selected against and was the reason for the lost fluorescent 
signal over time.  Therefore, we decided to remedy the loss of GFP expression by 
generating clonal cell lines.  As described previously, the oligoclonal cells were sorted by 
FACS for positive GFP expression. Single cells were sorted from high GFP expressing 
cells and sorted into a 96 well plate under sterile, tissue culture conditions.  The single 
cells were then cultured and examined under a fluorescent microscope for successful 
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clonal expansion and continued consistent GFP expression. After days of careful 
monitoring and culturing of the expanded clonal cell lines, we tested the generated clonal 
cells and observed that GFP expression over weeks of culture and observed the GFP 
expression to remain unchanged over time (Figure A1.3).  When we tested our clonal 
cells by stimulating them with our lab strains of S. pneumoniae to evaluate their relative 
utilities, we observed consistent patterns of NF-κB activation (Figure A1.4—referred to 
in Figure 2A). 
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APPENDIX 2: PRELIMINARY GENOMIC INVESTIGATIONS  
In Appendix 2, we carried out preliminary experiments to examine the potential 
for genomic contributions in the regulation of varying NF-κB activation in pneumococcal 
isolates.  Among serotype-matched isolates with identical multilocus sequence types 
(MLSTs), the presence of both high and low activators revealed that genomic elements 
driving macrophage responses segregate from serotype and MLST (Figure A2.1). In 
addition, comparisons of capsule-switched variants (in which different capsules are 
inserted into an otherwise identical pneumococcal genomic backbone) revealed that 
distinct capsules of the same serotype can differentially activate macrophage NF-κB 
(Figure A2.2), suggesting capsule gene variants that do not influence serotype are 
sufficient to determine macrophage responses. More work needs to be done to fully 
explore these findings and the mechanism of how these capsule gene variants that do not 
influence serotype function need to be elucidated.  However, the prospects that 
pneumococcal capsule gene variants may have a regulatory role in macrophage NF-κB 
activation, is a novel concept in the field of host-microbe interactions and should be 
investigated.   	
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Figure A2. Select Pneumococcal Elements Determine the Degree of Macrophage 
NF-κB Activation. (A2.1) Differences in NF-κB activation among serotype-matched isolates with 
identical multilocus sequence types (MLSTs). Both high and low NF-κB activators 
showed that genomic elements driving macrophage responses segregate from 
serotype and MLST. Each point represents a different pneumococcal isolate within 
the respective MLST group.  Horizontal lines indicate median values.  
(A2.2) Comparisons of capsule-switched variants (in which different capsules are 
inserted into an otherwise identical pneumococcal genomic backbone) reveal distinct 
capsules of the same serotype can differentially activate macrophage NF-κB.  P value 
was determined by Mann-Whitney U test *p< 0.05. 
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